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Cyclic enaminones, which possess vinylogous amide functionality in a closed ring 
structure, have been extensively studied and their versatility continues to spark 
interest in newer and more efficient methods for their enantiospecific synthesis and 
chemical modification.  Due to their unique structural and chemical properties, 
enaminones are of interest in natural product and diversity-oriented synthesis (DOS). 
Many biologically active natural products and alkaloids belong to the indolizidine, 
pyrrolizidine, and quinolizidine classes of molecules. They can be synthesized via 
enaminones as intermediates. Therefore, the goal of this project was to develop a 
general methodology for the facile and enantiospecific synthesis of the enaminone 
scaffolds and then generate a library using this method. 
 
It was hypothesized that one-pot Boc deprotection/cyclization of β-
hydroxylaminoynones would render N-oxy enaminones, which can be easily 
converted to enaminones by reductive cleavage of the N-O bond. Due to 
complications observed with such type of chemistry, the route was modified and a 
one-pot TBS deprotection/cyclization of β-hydroxylaminoynones was carried out. 
This approach yielded novel seven-membered N-O heterocyclic compounds. The 
 iv 
mechanism is thought to be a 7-endo-dig cyclization to yield seven-membered 3,4-
dihydro-1,2-oxazepin-5(2H)-ones. Reductive cleavage of the N-O bond in 3,4-
dihydro-1,2-oxazepin-5(2H)-ones rendered 2,3-dihydropyridin-4-(1H)-ones 
(enaminones). Thus, the 7-membered novel oxazepinone scaffold and the known 
enaminone scaffold can be used for constructing diverse compound libraries. 
Additional chemical transformations can also be carried out on these scaffolds to 
obtain additional diverse chemotypes. 
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1.  Background 
 
1.1 Introduction 
  About 1060 small molecules with molecular weight less than 500 exist in the 
“Chemical Diversity Space.” Only 108 molecules have been synthesized or isolated 
from natural sources so far.1 Heterocyclic compounds containing nitrogen contribute 
to a major portion of various classes of therapeutic agents. In many cases, these 
structures contain a piperidine moiety.2,3  
 
Figure 1. Enaminones as Important Intermediates for Various Alkaloids 
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Cyclic Z-enaminones are a very well known class of molecules that have been 
extensively studied and their versatility and unique chemical properties continue to 
spark interest in novel and more efficient methods for their enantiospecific synthesis.4 
Enaminones are very important intermediates in the synthesis of alkaloids10 (Figure 
1). 
 
Figure 2. Structural Differences amongst Amide, Enamine and Enaminones 
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Figure 2 shows the structural differences amongst an amide, an enamine, an 
enaminone and a cyclic Z-enaminone. Enamines can be described as vinylogous 
amines, whereas, enaminones are vinylogous amides. Cyclic Z-enaminones possess 
the vinylogous amide functionality in a closed ring structure. Enaminones are 
comparatively more stable and reactive than the corresponding enamines, which are 
sensitive to oxidation and hydrolysis and sometimes difficult to isolate.5 The 
conjugation of the enamines to a carbonyl functionality weakens their reactivity and 
makes them less robust than amides, but responsible for their versatile and unique 
properties.6  
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Figure 3. The Versatile 2,3-Dihydro-4-pyridones 
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A large variety of transformations are possible on this unique scaffold as shown in 
Figure 3.7,10 At position 1, the nitrogen atom can carry a variety of moieties such as a 
proton, different alkyl groups or a carboxylate. The C-2 position bears a substituent 
R1. A variety of substituents can contribute to additional diversity. Also, by changing 
the stereochemistry at the C-2 position, one can obtain different enantiomers. The C-3 
position is acidic due to the presence of adjacent carbonyl group. Various types of 
substitution are possible at C-3 position via enolate alkylation or acetoxylation. A 
large number of transformations can be carried out on the carbonyl at C-4. Some of 
the examples of these transformations are 1,2-addition at C-4 using reagents such as 
Grignard reagents, alkyl or aryl lithium reagents, etc. The C-5 position is relatively 
nucleophilic, so a variety of electrophilic additions (e.g. addition of iodine) are 
possible on the C-5 carbon. The double bond between C-5 and C-6 can be subjected 
to a [2+2] photocycloaddition with dienophiles. The C-6 position can be subjected to 
various 1,4-addition reactions. Some of the transformations include 1,4-hydride 
addition by using reagents such as L-Selectride, Michael addition using copper 
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reagents, etc. Therefore, the unique structural and chemical properties of enaminones 
is of interest in natural product and diversity-oriented synthesis (DOS).8   
 
1.2 Syntheses of Enaminones 
Over the last 20 years various routes for synthesizing enaminones have been 
established. All these methods aim to prepare the enaminones in high yields and 
excellent steroselectivities by employing either various chiral catalysts or using chiral 
non-racemic starting materials. Methods that are effective in generating these unique 
scaffolds are discussed below.    
 
1.2.1 Ishihara’s Strategy 
In 1997, Kazuaki Ishihara et al. reported a facile synthesis of enaminones by 
employing the asymmetric aza Diels-Alder reaction of imines.9  
Scheme 1. Ishihara’s Approach  
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The chiral boron complex (R)-1 is prepared in situ by stirring equimolar amounts of 
optically active (R)-binaphthol and triphenyl borate in dichloromethane at room 
temperature for 1 hour in the presence of 4Å molecular sieves.  The chiral complex 
(R)-1 thus formed in situ is used to promote the aza Diels-Alder reaction of the imine 
with the Danishefsky diene in the presence of 4Å molecular sieves at -78 °C for 
several hours. After usual workup and purification by column chromatography, the 
enaminone 2 is isolated in 75% yield and 82% ee. The new chiral boron reagent (R)-1 
offers various advantages including the following. (1) Both chiral binaphthol and 
phenyl borate are available commercially and the catalyst can be easily generated. (2) 
Isolation is not difficult and binaphthol can be recovered quantitatively. (3) Either 
enantiomer of the product can be synthesized since the required reagents are readily 
available in both R and S forms.   
 
1.2.2 Comins’ Strategy 
In 1999, Daniel Comins reported a very efficient method to synthesize chiral non-
racemic enaminones (Scheme 2).10 In this method, a chiral acylpyridinium salt is 
prepared in situ from 4-methoxy-3-(triisopropylsilyl)pyridine (3) and (-)-trans-2-(a-
cumyl)cyclohexyl chloroformate (TCC chloroformate). This is then treated with a 
Grignard reagent and an aqueous workup to yield the N-protected enaminone 4 with 
very good diastereoselectivities (85-95%). After the major diastereomer is separated 
by either recrystallization or column chromatography, standard chemical 
 6 
transformations are performed to remove and recover the chiral auxiliary and cleave 
the triisopropylsilyl group in order to get the free enaminone 5. 
Scheme 2. Comins’ Approach 
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1.2.3 Georg’s Strategy 
In 2006, the Georg group developed a novel method for the intramolecular 
cyclization of amino ynones to yield the enaminones (Scheme 3).11 In this facile 
synthesis of enantiopure enaminones, commercially available enantiopure α-amino 
acids are converted into α-diazoketone by treatment with diazomethane, which is 
generated in situ.  This is then reacted with silver triflate in the presence of 
triethylamine and free Weinreb amine (generated by distillation of the Weinreb salt in 
the presence of a base like DBU or Hunig’s Base) to generate a Weinreb amide. The 
addition of an alkynyl Grignard reagent to the amide furnishes the ynone 
intermediate.  
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Scheme 3. Georg’s Approach 
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The final cyclization is carried out by subjecting the ynone to either of the conditions 
from (a), (b) or (c). In condition (a), the ynone is treated with a solution of 
concentrated HCl in dioxane followed by treatment with potassium carbonate in 
methanol as solvent. In condition (b), the ynone is dissolved in anhydrous CH2Cl2 
under an argon atmosphere at -78 °C and a solution of TMS-I CH2Cl2 is added. After 
allowing the reaction mixture to warm to room temperature, more TMS-I is added 
and then this is followed by treatment with potassium carbonate in methanol as 
solvent. In condition (c), the ynones are subjected to a solution of NaI and formic acid 
followed by treatment with potassium carbonate in methanol as solvent. After column 
chromatography the enaminones can be obtained in very good yields (43% to 96%). 
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Limitations 
The Ishihara method does not provide particularly high selectivity and hence the ee is 
compromised and the yields are also not good. Although the method developed by 
Comins is by far the most frequently employed to synthesize chiral asymmetric 
enaminones, it does not provide a direct route for the synthesis of enaminones. The 
Georg method requires β-amino acids as starting materials. Although these are readily 
available, they can be as expensive as $200/gram. The alternate route is to generate 
them by homologation. In this case, although the homologation method is readily 
scalable and calls for relatively inexpensive starting materials, the process gives 
moderate yields. The method requires large quantities of diazomethane that is 
extremely flammable and hazardous to handle. With respect to the diversity point of 
view the availability of amino acids is limited. So there is a limitation on the variety 
of products one can obtain.  
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2. Strategy 
 
Optically active β-amino acids have been of great interest to medicinal chemists all 
over the world due to their presence in various natural products.12 Their versatility 
allows a number of chemical transformations that can be performed to convert them 
into yet more useful intermediates. Although homologation of α-amino acids is a 
direct method to generate the β-amino acids, the conjugate addition of amines or 
equivalent nucleophiles to the α,β-unsaturated carbonyl compounds is an alternate 
practical and flexible strategy for generating β-amino acid-like molecules.13, 14 A 
number of recent publications focusing on the same topic include the Michael 
addition of aldoximes,15 hydrazoic acid,16 trimethylsilyl azide17 and 
hydroxylamines.18 Often these reactions are promoted by catalytic quantities of chiral 
metal complexes15-18 and simple peptides.16 For reactions with weaker nitrogen 
nucleophiles like carbamates, catalytic activation of α,β-unsaturated carbonyl 
compounds is required and is more difficult.  
               In 2005, David MacMillan developed a strategy of generating β-amino 
aldehydes and the corresponding β-amino acids by enantioselective organocatalytic 
conjugate addition of N-silyloxycarbamate nucleophiles to α,β-unsaturated aldehydes 
(Scheme 4).19  
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Scheme 4. Enantioselective Organocatalytic Amine Conjugate Addition 
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The synthesis employed two different types of amines, amine A and amine B (Figure 
4). The amine A was chosen as a nucleophilic component. N-silyloxycarbamates were 
found to be suitable as amine A on the basis of two criteria: 
1) The α-effect due to the N-O functionality will increase nucleophilicity at the 
nitrogen center, while the carbamate functionality will furnish effectively non-
basic β-amino aldehydes (silyloxycarbamate N-H, estimated pKa ~ 9.0). 19, 20  
2) They will selectively function as 1,4-addition nucleophiles and will not 
participate in the iminium activation. 
Figure 4. Selectivity of Amines and Nucleophilicity Enhancement of Carbamate by 
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Amine B was selected as an iminium activating catalyst. An imidazolidinone amine 
was found to be useful because of its role in asymmetric iminium activation of enals 
and enones while not participating in the 1,4-addition.21 Figure 4 shows the function 
of both amine A and amine B. The transition state TS-1 is desired in order to obtain 
the required products. In TS-1, the amine B selectively forms an iminium species 
with the α,β-unsaturated aldehydes. Then the amine A, selectively acting as a 
nucleophile, is added in a Michael fashion onto the iminium species. In the 
undesirable transition state TS-2, amine A acts as a nucleophile as well forming 
iminium species with the enal.  Since this type of transition state is undesirable, the 
design of amine A becomes extremely important. Figure 4 also explains the change in 
the nucleophilicity at the nitrogen center. Due to the α-effect promoted by the oxygen 
atom attached directly to the nitrogen atom, the energy of the Highest Occupied 
Molecular Orbital (HOMO) on the nitrogen atom is raised. Hence the N-
silyloxycarbamate is more nucleophilic than the corresponding carbamate molecule. 
But again, due to the presence of the carboxylate functionality on the nitrogen atom, 
the nucleophilicity is controlled and the resultant N-silyloxycarbamate molecule is 
effectively non-basic, with the pKa of N-H ~ 9.0 in the N-silyloxycarbamate 
molecules.20 
                   Choosing the specific nucleophiles and catalyst ensured reaction progress 
under kinetic (asymmetric) control with stereodefining nitrogen atom addition 
accompanied by irreversible loss of the nucleophile’s proton. This avoided the 
possibility of an equilibrium-controlled process with reversible addition of the 
 12 
nitrogen nucleophile and hence generating racemic products. The Figure 5 shows a 
detailed mechanism for conjugate addition of nucleophilic the N-silyloxycarbamate to 
α,β-unsaturated aldehydes.  
Figure 5. Mechanism of Conjugate Addition 
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We decided to employ this well developed strategy to generate β-amino aldehydes for 
the synthesis of enaminones. A retrosynthetic analysis is summarized in Scheme 5.  
Scheme 5. Retrosynthetic Analysis 
Boc
N
OTBS
R1
O
R2
Oxidation
Boc
N
OTBS
R1
OH
R2
Alkynylation
Boc
N
OTBS
R1 O
Boc deprotection / 
cyclization
Organocatalytic amine
conjugate addition
Boc
N
H
OTBS
R1 O
N
O
R2R1
H
N
O
R2R1
OH
N-O bond 
cleavage
1211
13
1415
16
17  
 
 13 
Our approach involves formation of N-oxygenated enaminones 12, which can be 
subjected to N-O bond cleavage conditions such as using SmI2 or Zn/AcOH in order 
to generate the enaminones 11. The N-oxy enaminones 12 can be generated by one-
pot Boc-deprotection/cyclization of the ynone intermediates 13. This can be achieved 
by using the conditions for enaminone generation that were previously developed in 
the Georg group.11 The ynones 13 can be synthesized by oxidation of the 
corresponding propargyl alcohols 14. The propargyl alcohols 14 can be constructed 
by nucleophilic addition of alkynyl nucleophiles (alkynyl Grignard reagents or 
alkynyl lithium reagents) to the β-amino aldehydes 15. The β-amino aldehydes 15 
can be synthesized according to MacMillan’s protocol. Hence within five steps the 
enaminones can be generated. The striking feature of these enaminones is the 
substituent diversity one can obtain with this approach. Instead of starting with only 
20 α-amino acids, we can generate nearly infinite number of compounds from a large 
variety of enals and alkynes. Also, we avoid using hazardous materials like 
diazomethane. This synthetic plan can render a library of enaminones and this is of 
high interest to a research program in natural product and diversity-oriented synthesis 
(DOS).8  
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3. Synthesis, Results and Discussions 
3.1 Synthesis of β-Amino Aldehydes 1519 
 
The β-amino aldehydes were prepared according to the strategy developed by David 
MacMillan. The synthesis of these aldehydes required tert-butyl-(tert-
butyldimethylsilyloxy)carbamate (16) and α,β-unsaturated aldehydes 17 as starting 
materials.  
 
3.1.1 Synthesis of tert-Butyl-(tert-butyldimethylsilyloxy)carbamate (16) 
The N-silyloxycarbamate nucleophile was synthesized starting with commercially 
available tert-butyl-N-hydroxycarbamate and TBS chloride (Scheme 6). tert-Butyl-N-
hydroxycarbamate, TBS-chloride and triethylamine were stirred overnight in CH2Cl2 
as solvent.  After work-up and column chromatography, tert-butyl-(tert-
butyldimethylsilyloxy)carbamate (16) was obtained in 94% as a pure, low melting 
solid (reported yield = 92%).  
Scheme 6 
N
H
OH
O
O Si
Cl
TEA, DCM
0 oC to rt
    94%
Boc
N
H
OTBS
16  
 
3.1.2 Synthesis of α,β-Unsaturated Aldehydes 17 
Some of the α,β-unsaturated aldehydes such as 2-hexenal and crotonaldehyde 
required for preparing β-amino aldehydes, were available commercially. But in order 
 15 
to introduce diversity, we decided to synthesize other enals starting from the 
corresponding aldehydes. In order to achieve this, we followed a strategy developed 
by Zhang et al.21 The starting aldehydes 18 and triphenylphosphoranylidene 
acetaldehyde (19) were refluxed in toluene under inert argon atmosphere (Table 1). 
After column chromatography, pure α,β-unsaturated aldehydes (17a and 17b) were 
obtained in good (81% and 85% respectively) yields.  
Table 1. Synthesis of α,β-Unsaturated Aldehydes 17 
R O Ph3P CH CHO
Toluene, reflux
      4-5 h
R O
17
argon
18 19  
Entry R Product  Yield (%) 
1 PhthN-CH2 
O
N
O
O
17a  
81 
2 BnO-CH2 
O
17b
BnO
 
85 
 
3.1.3 Synthesis of β-Amino Aldehydes 15 
The next step was to synthesize β-amino aldehydes. Using MacMillan’s protocol,19 
the corresponding β-amino aldehydes were synthesized (Table 2).  
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Table 2. Synthesis β-Amino Aldehydes 
N
H
OTBS
R1 O
N
OTBS
R1 O
CHCl3, -20 
oC
  24 h - 36 h
N
N
H Ph
Me O
. pTSA
Boc
Boc
16 17 15  
Entry R1 Product Yield 
(%) 
ee (%) Time (h) 
1 n-Pr Boc
N
OTBS
n-Pr O  
15a 
73 92 24 
2 Me Boc
N
OTBS
Me O  
15b 
75 --* 24 
3 PhthN-CH2 Boc
N
OTBS
O
N
O
O
 
15c 
39 87 36 
4 BnO-CH2 Boc
N
OTBS
O
BnO
 
15d 
68 --* 36 
* to be determined 
 17 
The required β-amino aldehydes were obtained in good yields. The enantiomeric 
excess (%) values of the aldehydes were determined using different strategies. For 
aldehyde 15a, the optical rotation exactly matched with the literature value19 ([α]D25 = 
-1.52 (c = 0.500, CHCl3)) and hence it was concluded that the % ee value would be 
the same as given in the literature (92%). The aldehyde 15c, was further treated with 
acetone-water (4:1) and pTSA.H2O for 12 hours. After usual workup and purification 
by column chromatography (20% EtOAc/hexanes), pure (3S,5S)-tert-Butyl-3-(N-
methylphthalimido)-5-hydroxyisoxazolidine-2-carboxylate was isolated. Optical 
rotation value of this sample exactly matched with that of the literature value ([α]D25 
= -60.0 (c = 0.600, CHCl3)) and hence it was concluded that the % ee value would be 
the same as given in the literature (87%). We first tried to separate the enantiomers of 
aldehydes 15b and 15d by using chiral HPLC (on a Chiralcel-OD column), but we 
found them to be inseparable. Therefore, both the aldehydes were converted to the 
corresponding alcohols by NaBH4 reduction. These were then coupled with the 
Mosher’s acid chloride to yield diastereomeric mixtures of Mosher esters. The 19F 
NMR analysis was carried out on these esters. Due to some ambiguity with respect to 
the NMR signals, determination of %ee was not possible. Our future plan includes 
deprotection of the Boc group from the aldehydes and subsequent protection with the 
Cbz group. This will render compounds that are known in the literature, and hence by 
merely comparing the optical rotation, the %ee value could be determined.  
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3.2 Synthesis of Propargyl Alcohols 14 
The β-amino aldehydes were next reacted with various alkynyl nucleophiles. We 
screened several commercially available acetylenes. Active alkynyl nucleophiles can 
be generated by a combination of alkyl or aryl terminal acetylenes and a strong base 
like n-BuLi. Alternatively alkynyl Grignard reagents can be used. We decided to 
employ both ways as per the availability of the reagents. The alkynyl nucleophile was 
either generated or used directly (if commercially available) in THF. A THF solution 
of β-amino aldehyde was added to the nucleophile solution at -78 °C and stirred for 
4-5 h. The NMR spectra of the reaction products revealed that the alcohols were 
obtained as 1:1 mixture of two diastereomers. Table 3 shows the structures of the 
propargyl alcohols synthesized. 
Table 3. Synthesis of Propargyl Alcohols 14 
Boc
N
OTBS
R1 O
R2
n-BuLi, THF
   -78 oC
R2 MgBr
Boc
N
OTBS
R1
OH
R2
or
THF, -78 oC
15 14
 
Entry R1 R2 Product  Yield 
(%) 
1 n-Pr Ph Boc
N
OTBS
n-Pr
OH
 
14a 
64 
 19 
2 n-Pr 4-MeO(C6H4) Boc
N
OTBS
n-Pr
OH
OMe  
14b 
33 
3 n-Pr 4-CF3(C6H4) Boc
N
OTBS
n-Pr
OH
CF3  
14c 
83 
4 n-Pr 3-thiophenyl Boc
N
OTBS
n-Pr
OH
S
 
14d 
26 
5 n-Pr Me Boc
N
OTBS
n-Pr
OH
Me  
14e 
55 
6 n-Pr t-Bu Boc
N
OTBS
n-Pr
OH
 
14f 
70 
 20 
7 Me 4-MeO(C6H4) Boc
N
OTBS
Me
OH
OMe  
14g 
59 
8 PhthN-CH2 4-MeO(C6H4) Boc
N
OTBS
N
OH
OMe
O
O
 
14h 
21 
9 BnO-CH2 4-MeO(C6H4) Boc
N
OTBS
OH
OMe
BnO
 
14i 
46 
 
3.3 Synthesis of Ynones 13 
The next step was the oxidation of the propargyl alcohols to convert them into 
alkynyl ketones. There are several methods to achieve this transformation, such as 
Dess-Martin, Swern, or the use of chromium reagents or MnO2. We decided to 
employ MnO2 oxidation of our propargyl alcohols. CH2Cl2 was chosen as a solvent. 
However, even after an overnight stirring of a propargyl alcohol and excess MnO2 in 
refluxing CH2Cl2, the reaction did not go to completion (less than 50% as shown by 
TLC). We therefore employed a higher boiling solvent, 1,2-dichloroethane (DCE), 
 21 
which boils around 115 °C and possesses similar characteristics to CH2Cl2. We 
dissolved our propargyl alcohols in DCE, added excess of MnO2 and refluxed the 
mixture overnight. Table 4 shows the structures and yields of the various ynones. 
 
Table 4. Synthesis of Ynones 13 
Boc
N
OTBS
R1
OH
MnO2, DCE, Reflux
R2
14 13
Boc
N
OTBS
R1
O
R2
 
Entry R1 R2 Product Yield 
(%) 
1 n-Pr Ph Boc
N
OTBS
n-Pr
O
 
13a 
70 
2 n-Pr 4-MeO(C6H4) Boc
N
OTBS
n-Pr
O
OMe  
13b 
68 
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3 n-Pr 4-CF3(C6H4) Boc
N
OTBS
n-Pr
O
CF3  
13c 
90 
4 n-Pr 3-thiophenyl Boc
N
OTBS
n-Pr
O
S
 
13d 
 
100 
5 n-Pr Me Boc
N
OTBS
n-Pr
O
Me  
13e 
77 
6 n-Pr t-Bu Boc
N
OTBS
n-Pr
O
 
13f 
90 
7 Me 4-MeO(C6H4) Boc
N
OTBS
Me
O
OMe  
13g 
54 
 23 
8 PhthN-CH2 4-MeO(C6H4) Boc
N
OTBS
N
O
OMe
O
O
 
13h 
100 
9 BnO-CH2 4-MeO(C6H4) Boc
N
OTBS
O
OMe
BnO
 
13i 
88 
 
In most of the cases, the yields were good. All the ynones were used crude for the 
next reactions, since the TLC showed a single, clear spot and the NMR showed more 
than 95% purity.  
 
3.4 Synthesis of N-oxy Enaminones 12 
The next step was a one step Boc deprotection/cyclization. The ynone (S)-tert-butyl 
tert-butyldimethylsilyloxy(6-oxo-8-phenyloct-7-yn-4-yl)carbamate (13a) was 
subjected to the cyclization conditions developed previously in the Georg laboratory. 
After treatment of 13a with 4N HCl/Dioxane, MeOH and excess K2CO3 were added 
(Scheme 7).  
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Scheme 7. Unsuccessful Attempt of Cyclization 
1. 4N HCl/Dioxane
2. Excess K2CO3, 
    MeOH
N
O
OH
n-Pr
Not seen,instead 
complete decomposition
was observed on TLC.
Boc
N
OTBS
n-Pr
O
13a
 
 
After the usual workup, the TLC showed complete decomposition of the substrate. 
This showed that the cyclization conditions are not suitable for these types of 
substrates. Repeating the experiments several times, with the same ynone (13a) and 
other ynones, gave the same results. One of the possible reasons for this observation 
was the use of strong 4N HCl. Probably the highly concentrated protic acid like HCl, 
deprotected both the Boc and the TBS group and decomposed the product. In the 
course of the reaction, both Boc and TBS can be removed simultaneously, creating 
complex mixture of products. Although, we had anticipated the removal of the TBS 
group in the course of the reaction, we had not expected the simultaneous 
deprotection.  
 
3.5 Synthesis of Novel 7-Membered Oxazepinones 20 
Taking into consideration the fact that both the Boc and TBS group can be 
deprotected by strong acid, we decided to use an orthogonal strategy, wherein only 
one group will be deprotected at a time. After a literature survey, we found that most 
of the methods deprotect the Boc group by acidic conditions, to which the TBS group 
 25 
is very sensitive as well. We therefore decided to keep the Boc group and deprotect 
the TBS group first. We thought this would render us with either a free hydroxyl if 
quenched by a proton, which could then be reprotected with another protecting group. 
The other possibility was the 7-endo-dig addition of the free Boc-N-O anion onto the 
triple bond yielding the unusual and novel N-O-heptacyclic enones a.k.a. 
oxazepinones. We dissolved the ynone (S)-tert-butyl tert-butyldimethylsilyloxy(6-
oxonon-7-yn-4-yl)carbamate (13e) in THF and to this mixture, 1M TBAF solution in 
THF was slowly added in a dropwise manner at room temperature (Table 5).  
Table 5. Synthesis of Novel Oxazepinones 20 
N O
O
R2
Boc
R1
TBAF, THF,
 rt, 1-2 min
2013
Boc
N
OTBS
R1
O
R2
 
Entry R1 R2 Product Yield (%) 
1 n-Pr Me 
N O
O
Me
Boc
n-Pr
 
20e 
73 
2 n-Pr t-Bu 
N O
O
Boc
n-Pr
 
20f 
52 
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Within few seconds after complete addition of the TBAF solution, the color of the 
reaction mixture changed from light yellow to dark brown. The TLC analysis of this 
mixture at this stage showed complete absence of the starting ynone and a single spot 
of the product. We decided to quench the reaction with silica gel as a very mild 
source of protons. After column chromatography, the product was obtained in 73% 
yield. NMR analysis of this yet unknown product 20e revealed that it was indeed the 
novel heptacyclic oxazepinone 20e. We subjected ynone (S)-tert-butyl tert-
butyldimethylsilyloxy(9,9-dimethyl-6-oxodec-7-yn-4-yl)carbamate (13f) to similar 
conditions and found that the product obtained this time was again a novel 
heptacyclic enone 20f. Table 5 shows the structures of products and yields. We next 
subjected the ynone (S)-tert-butyl tert-butyldimethylsilyloxy(6-oxo-8-phenyloct-7-
yn-4-yl)carbamate (13a) (Table 6) to the same one pot TBS deprotection/cyclization 
conditions expecting to obtain another oxazepinone. We observed an interesting trend 
in this conversion. For all the cases along with the case of 13a, when R2 was 
aromatic, the 1H NMR spectra were found to be characteristic. The olefinic proton 
was found around 5.81-5.95 ppm in 1H NMR spectra, while for previously 
synthesized oxazepinones, 20e and 20f, the olefinic protons were seen around 5.31-
5.33 ppm. Also, the ortho-protons of the phenyl ring and thiophene were found much 
more deshielded than they would be in a normal case. Therefore we initially thought 
that the ynones bearing aromatic R2 substituents might have cyclized by 6-exo-dig 
mechanism to 6-membered oxa-piperidinones (21) possessing E-stereochemistry 
(Figure 6). A logical explanation for this observation was thought to be the 
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anisotropic effect of the carbonyl group. If the aromatic ring attached to the double 
bond were on the same side as that of the carbonyl group, then the ortho-protons 
would be more deshielded due to the polarizable C=O bond. Generally, ortho protons 
of a phenyl ring (or substituted phenyl ring) would show a chemical shift at 7.43-7.55 
ppm, but in our cases the ortho protons of the aromatic substituents showed a 
chemical shift at 7.72-8.07 ppm depending upon the substituent on the aromatic ring.  
Figure 6. Structure of 6-membered oxa-piperidinones 21 
N
O
R1
O
Boc
R2
H
21
R2 = Aromatic  
 
But, on further studies of both the 13C and 1H NMR spectra, it was found that these 
compounds are all 7-membered oxazepinones 20. In order to confirm the structures of 
these compounds we subjected them to reductive N-O bond cleavage conditions. A 
1H and 13C NMR analysis of the cleaved products was carried out. If the starting 
compounds were indeed 6-membered oxa-piperidinones 21 then the reaction products 
21a should have been the 1,2-diketones (Figure 7). But since we could clearly see the 
presence of an enol proton and an olefinic proton in the 1H NMR, it was more likely 
that the cleaved products were 1,3-diketones 22, in which case it is possible for them 
to exist in the ketoenol forms. The olefinic protons in these N-O bond cleaved 
compounds 22 were seen at around 6.06 ppm in the 1H NMR and the ortho protons of 
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the aromatic rings were found more deshielded (downfield) exactly as they were 
found in starting materials.  
Figure 7. Reductive Cleavage of the N-O bond  
SmI2, MeOH, 
rt, 10 mins
21a
N
O
R1
O
Boc
R2
H
21
NHR1
O
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R2
H
O Equ. 1
 
SmI2, MeOH, 
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20 22
N O
O
R2
Boc
R1
H
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O
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Boc
R1
H
HO
Equ. 2
 
 
Only one ketone carbonyl carbon was clearly seen in the 13C NMR at around 192 
ppm. The olefinic carbon bearing both an aromatic substituent and a hydroxyl group 
was also clearly seen at around 179 ppm. The other olefinic carbon bearing a proton 
was seen around 97 ppm. We compared the NMR analyses of our 1,3-diketones to the 
structurally similar β-keto-trimethylsilyl-enol-ethers.23 We found that the chemical 
shifts of protons and carbons of our 1,3-diketones were comparable with the literature 
values. Hence, we concluded that all cyclization products are oxazepinones. We also 
reconfirmed the structure of oxazepinone 20e by NMR analysis of its corresponding 
N-O cleaved structure (Figure 8). In this case the 1H NMR of a methyl group attached 
to the olefinic carbon was observed at around 2.1 ppm as a singlet, which indicated 
that the structure was indeed the 1,3-diketone. Had the starting cyclic product been a 
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6-membered oxa-piperidinone then the 1H NMR of the N-O cleaved structure should 
have shown the methyl group as a triplet.  
Figure 8. Reductive Cleavage of N-O bond of Oxazepinone 20e 
SmI2, MeOH, 
rt, 10 mins
20e 22e
N O
O
Me
Boc
n-Pr
H
NH
O
Me
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n-Pr
H
HO
 
 
Table 6 shows the 7-membered oxazepinones 20 with aromatic R2 substituents on the 
ynone functionality. 
Table 6. Synthesis of Novel Oxazepinones 20 
N O
O
R2
Boc
R1
TBAF, THF,
 rt, 1-2 min
2013
Boc
N
OTBS
R1
O
R2
 
Entry R1 R2 Product Yield 
(%) 
1 n-Pr Ph 
N O
O
Boc
n-Pr
 
20a 
77 
 30 
2 n-Pr 4-MeO(C6H4) 
N O
O
Boc
n-Pr
OMe
 
20b 
91 
3 n-Pr 4-CF3(C6H4) 
N O
O
Boc
n-Pr
CF3
 
20c 
23 
 
4 n-Pr 3-thiophenyl 
N O
O
Boc
n-Pr S
 
20d 
64 
5 Me 4-MeO(C6H4) 
N O
O
Boc
Me
OMe
 
20g 
44 
6 PhthN-CH2 4-MeO(C6H4) 
N O
O
Boc
OMe
N
O
O
 
20h 
 
43 
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7 BnO-CH2 4-MeO(C6H4) 
N O
O
Boc
OMe
BnO
 
20i 
48 
 
3.6 Proposed Mechanism of Cyclization 
A mechanism for the cyclization of ynones to enaminones has been proposed by our 
group for the previously developed methodology (Scheme 8).11  
 
Scheme 8. Mechanism of Cyclization of Ynones to Enaminones 
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In this mechanism, the chloride anion was found to attack the triple bond of the 
ynone, forming either the vinyl chloride or the dichloride.11 Methanol would act as a 
nucleophilic solvent and convert the monochloro and dichloro species into a geminal 
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methoxy chloro species. This intermediate would lead to the enaminone by losing the 
chloride anion. Based on this mechanism, we thought of adding fluoride anion to the 
β-hydroxylamino ynone. In order to confirm this mechanism, we carried out NMR 
studies. In this model study, 0.0500 g (0.159 mmol, 1.00 equiv) of tert-butyl 2-(2-
oxo-4-phenylbut-3-ynyl)pyrrolidine-1-carboxylate (substrate X) was dissolved in 
THF-d8 (1.00 mL) in an NMR tube (Table 7).  
Table 7. NMR Studies for Confirmation of the Mechanism of Cyclization 
N
Boc
O
N
Boc
O
FTBAF, THF-d8
Substrate X Product Y  
TBAF (equivs) Observations 
0 SM peaks 
0.1 SM and TBAF peaks 
0.3 SM and TBAF peaks 
1 SM peaks started to fade away, large TBAF peaks 
1.5 SM peaks almost faded away, no product peaks, large TBAF peaks 
3 SM peaks completely faded away, no product peaks, large TBAF peaks 
 
TBAF solution was added to this solution in increasing amounts. After every addition 
of a TBAF equivalent, the 1H NMR spectrum of the mixture was recorded for 
identifying any formation of tert-butyl 2-(4-fluoro-2-oxo-4-phenylbut-3-
enyl)pyrrolidine-1-carboxylate product Y. Table 7 summarizes the observations of 
the experiment. From the observations it was clear that the fluoride anion did not 
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attack the triple bond of the ynone. We are therefore proposing that the addition of 
TBAF to the ynone leads to a TBS deprotected intermediate (Scheme 9). This 
intermediate can cyclize in 7-endo-trig manner. The free oxygen anion can attack the 
triple bond in Michael fashion followed by quenching with a proton forming the 7-
membered oxazepinones. 
Scheme 9. Proposed Mechanism for Cyclization 
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N
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O
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3.7 Synthetic Utility of Oxazepinones  
The newly formed 7-membered oxazepinones are structurally similar to the 
enaminones and therefore a variety of reactions can be performed with them. All the 
transformations that can be carried out on enaminones (Figure 1) should be possible 
with these compounds. This strategy can yield a wide number of large libraries. We 
decided to carry on a short 2-step transformation with our oxazepinones. 
1. N-O bond cleavage 
2. Boc deprotection 
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3.8 Synthesis of Enaminones 25 
The oxazepinones 20 were subjected to reductive cleavage by treatment with SmI2 
and MeOH as solvent (Figure 7, Equ. 2). The product was generally not isolated and 
purified but instead was taken as a crude to the next step. The intermediates were 
subjected to a Boc-deprotection reaction. Table 8 shows the structures and yields of 
the products. After usual work-up with a saturated solution of Na2CO3 and brine, the 
TLC analysis of the solution showed presence of only one compound. 1H and 13C 
NMR analysis revealed the formation of enaminones 25. 
 
Table 8. Synthesis of Enaminones 25 
1. SmI2, MeOH, 
     rt, 10 mins
2. TFA, DCM, rt
20
N O
O
R2
Boc
R1
H
N
H
O
R2
25
R1
 
 
Entry R1 R2 Product Yield (%) 
1 n-Pr Ph 
N
H
O
n-Pr
 
25a 
60 
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2 n-Pr 4-CF3(C6H4) 
N
H
O
n-Pr
CF3  
25c 
78 
3 n-Pr 3-thiophenyl 
N
H
O
n-Pr
S
 
25d 
 
88 
4 n-Pr Me 
N
H
O
Men-Pr
 
25e 
100 
5 n-Pr t-Bu 
N
H
O
n-Pr
 
25f 
  100 
6 BnO-CH2 4-MeO(C6H4) 
N
H
O
OMe
BnO
 
25i 
75 
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4. Conclusion 
 
In conclusion, we have synthesized one known and one novel scaffold. The 
cyclization of β-hydroxylamino ynones 13 furnished novel oxazepinones 20. TBS 
deprotection by TBAF promoted 7-endo-dig cyclization to furnish 3,4-dihydro-1,2-
oxazepin-5(2H)-ones 20. Reductive cleavage of the N-O bonds of intermediates 20 
yielded 2,3-dihydropyridin-4-(1H)-ones (enaminones) 25. Our original plan of 
preparing a library of enaminones is now possible via synthesis of novel oxazepinone 
intermediates. The newly prepared compounds constitute unique 7- and 6-membered 
scaffolds that can be used for the synthesis of diverse compound libraries. Additional 
chemical transformations such as nucleophilic addition to the double bond, 1,2-
addition, enolate alkylation and N-acylation can be carried out to obtain additional 
diverse chemotypes. The dihydropyridones intermediates 25 can be used to prepare 
important natural products such as the indolizidine alkaloids.6,22 Our future plans 
include submission of these compounds for biological testing in the NIH’s MLSCN.  
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5. Experimental Section 
General Information: 
All commercially available reagents and solvents were used without further purification. 
tert-Butyl hydroxycarbamate and all acetylenes were purchased from Sigma-Aldrich. All 
other chemicals and solvents were purchased from Acros Organics and Sigma-Aldrich. 
Organic solutions were concentrated under reduced pressure on a Büchi rotary 
evaporator. Flash column chromatography was carried out on silica gel. TLC was 
conducted on silica gel 250 micron, F254 plates. 1H NMR spectra were recorded on a 
Bruker 400 MHz NMR instrument. Chemical shifts are reported in ppm with TMS as 
an internal standard (TMS: 0.0 ppm). Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), 
integration and coupling constants (Hz). 13C NMR spectra were recorded on a Bruker 
100 MHz NMR spectrometer with complete proton decoupling. Chemical shifts are 
reported in ppm with the solvent as internal standard (CDCl3: 77.2 ppm). High-
resolution mass spectrometry was performed by the University of Minnesota Mass 
Spectroscopy Facility. IR spectra were recorded on a Perkin Elmer Spectrum 100 FT-
IR spectrometer and are reported in terms of frequency of absorption (cm-1). Optical 
rotations were measured on a Rudolph Research Analytical AUTOPOL® V polarimeter 
and concentration (c) is in g/100 mL. 
Experimental Procedures: 
O
N
O
O
17a  
(E)-4-(1,3-Dioxoisoindolin-2-yl)but-2-enal (17a): A toluene solution (80 mL) of 
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(triphenylphosphoranylidene)acetaldehyde (3.352 g, 10.57 mmol) and 
phthalimidoacetaldehyde (2.000 g, 10.57 mmol) was heated under reflux for 4-5 h 
under argon. The solvent was then removed under reduced pressure. Purification of 
the residue by silica gel column chromatography (30% EtOAc/hexane) provided the 
title compound as clear oil (1.8 g, 81% yield). IR (thin film) 1772, 1703, 1679, 1466, 
733 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.57 (m, 2H), 6.14 (m, 1H), 6.83 (m, 1H), 
7.76 (m, 2H), 7.89 (m, 2H), 9.56 (d, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 38.4, 
123.6, 131.8, 133.1, 134.3, 148.9, 167.5, 192.5 ppm; HRMS calculated for 
(C12H9NO3) required m/z [M+Na] 238.0480, found m/z 238.0484. 
 
O
17b
BnO
 
(E)-4-(Benzyloxy)but-2-enal (17b): A toluene solution (80 mL) of 
(triphenylphosphoranylidene)acetaldehyde (4.222 g, 13.32 mmol) and 
benzyloxyacetaldehyde (2.000 g, 13.32 mmol) was heated under reflux for 4-5 h 
under argon. The solvent was then removed under reduced pressure. Purification of 
the residue by silica gel column chromatography (20% EtOAc/hexane) provided the 
title compound as clear oil (2.0 g, 85% yield). IR (thin film) 3088, 3064, 3032, 2731, 
1690, 1642, 1454, 1027, 969, 740, 699 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.26 (m, 
2H), 4.57 (s, 2H), 6.39 (m, 1H), 6.83 (m, 1H), 7.30-7.35 (m, 5H), 9.55 (d, 1H) ppm; 
13C NMR (100 MHz, CDCl3) δ 68.5, 72.9, 127.6, 127.9, 128.4, 131.7, 137.4, 153.1, 
193.2 ppm; HRMS calculated for (C11H12O2) required m/z [M+Na] 199.0735, found 
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m/z 199.0734. 
 
General Procedure for the Conjugate Amination of Aldehydes: 
A round bottom flask equipped with a magnetic stir bar was charged with pTSA salt 
of (2R,5R)-5-benzyl-2-tert-butyl-3-methylimidazolidin-4-one (cat. I) and the 
appropriate enal in CHCl3 was cooled to -20 °C. tert-Butyl-(tert-
butyldimethylsilyloxy)carbamate (16) was then added in one portion and the reaction 
mixture was stirred at -20 °C. Upon completion of the reaction as determined by TLC 
analysis (24-36 h), the products were isolated as below.   
 
Boc
N
OTBS
Me O
15b  
(S)-tert-Butyl tert-Butyldimethylsilyloxy(4-oxobutan-2-yl)carbamate (15b): 
Prepared using cat. I.pTSA (176 mg, 0.404 mmol, 0.200 equiv), crotonaldehyde 
(0.507 mL, 6.06 mmol, 3.00 equiv) in CHCl3 (6 mL) at –20 °C. tert-Butyl-(tert-
butyldimethylsilyloxy)carbamate (16) (500.0 mg, 2.021 mmol, 1.000 equiv) was 
added in one portion and the reaction was maintained at –20 °C for 24 h. Purification 
by silica gel column chromatography (10% Et2O/hexane) provided the title compound 
as clear oil (480 mg, 75% yield, % ee). IR (thin film) 3430, 2958, 2931, 2849, 1728, 
1473, 1461, 1388, 1368, 1251, 1168 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.15 (s, 6H), 
0.95 (s, 9H), 1.24 (d, 3H), 1.48 (s, 9H), 2.60 (dd, 1H, J1 = 7.1 and J2 = 16.6 Hz), 2.80 
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(dd, 1H, J1 = 6.3 and J2 = 16.6 Hz), 4.39 (m, 1H), 9.78 (t, 1H, J = 1.9 Hz) ppm; 13C 
NMR (100 MHz, CDCl3) δ –4.4, 17.8, 18.2, 25.8, 28.2, 34.7, 47.8, 54.3, 81.9, 158.6, 
200.5 ppm; HRMS calculated for (C15H31NO4Si) requires m/z [M+Na] 340.1920, 
found m/z 340.1916. [α]25D = +4.00 (c = 0.500, CHCl3). 
 
N
O
O
O
N
Boc OTBS
15c  
(R)-tert-Butyl tert-Butyldimethylsilyloxy(1-(1,3-dioxoisoindolin-2-yl)-4-oxobutan-
2-yl)carbamate (15c): Prepared according to the general procedure using cat. 
I.pTSA (80.9 mg, 0.185 mmol, 0.200 equiv), (E)-4-(1,3-Dioxoisoindolin-2-yl)but-2-
enal (17a) (0.598 mg, 2.78 mmol, 3.00 equiv) in CHCl3 (2.78 mL) at –20 °C. tert-
Butyl-(tert-butyldimethylsilyloxy)carbamate (16) (229 mg, 0.926mmol, 1.00 equiv) 
was added in one portion and the reaction was maintained at –20 °C for 36 h. The 
reaction mixture was worked up according to the general procedure. Purification by 
silica gel column chromatography (30% EtOAc/hexane) provided the title compound 
as clear oil (168 mg, 39% yield, 87% ee). IR (thin film) 3442, 2945, 2909, 2849, 
1719, 1395, 1364, 1252, 1169 cm-1. 1H NMR (400 MHz, CDCl3) δ 0.09 (s, 3H), 0.14 
(s, 3H), 0.83 (s, 9H), 1.42 (s, 9H), 2.70 (dd, 1H, J1 = 6.1 and J2 = 17.2 Hz), 2.98 (dd, 
1H, J1 = 7.8 and J2 = 17.2 Hz), 3.79 (dd, 1H, J1 = 6.4 and J2 = 13.8 Hz), 4.11 (dd, 1H, 
J1 = 9.7 and J2 = 16.6 Hz), 4.59 (m, 1H), 7.68 (m, 2H), 7.81 (m, 2H), 9.73 (t, 1H, J = 
1.6 Hz) ppm; 13C NMR (100 MHz, CDCl3) δ –4.8, 18.2, 25.8, 28.2, 39.0, 44.7, 56.8, 
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82.2, 123.4, 133.9, 134.2, 157.7, 168.2, 199.2 ppm; HRMS calculated for 
(C23H34N2O6Si) requires m/z [M+Na] 485.2084, found m/z 485.2089. [α]25D = -27.0 (c 
= 0.500, CHCl3). The enantiomeric excess was determined by further derivatizing the 
title compound into (3R,5S)-tert-butyl 3-((1,3-dioxoisoindolin-2-yl)methyl)-5-
hydroxyisoxazolidine-2-carboxylate. The [α]25D value of this compound exactly 
matched with the literature value ( [α]25D = -60.0 (c = 0.600, CHCl3).  
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15d  
(R)-tert-Butyl 1-(Benzyloxy)-4-oxobutan-2-yl(tert-
butyldimethylsilyloxy)carbamate (15d): Prepared according to the general 
procedure using cat. I.pTSA (176 mg, 0.404 mmol, 0.200 equiv), (E)-4-
(Benzyloxy)but-2-enal (17b) (1.07 g, 6.06 mmol, 3.00 equiv) in CHCl3 (6 mL) at –20 
°C. tert-Butyl-(tert-butyldimethylsilyloxy)carbamate (16) (500.0 mg, 2.021 mmol, 
1.000 equiv) was added in one portion and the reaction was maintained at –20 °C for 
36 h. The reaction mixture was worked up according to the general procedure. 
Purification by silica gel column chromatography (20% Et2O/hexane) provided the 
title compound as clear oil (583 mg, 68% yield, % ee). IR (thin film) 3430, 2945, 
2930, 2858, 1728, 1479, 1455, 1388, 1368, 1310, 1251, 1168, 1109, 841, 786, 698 
cm-1. 1H NMR (400 MHz, CDCl3) δ 0.14 (s, 6H), 0.94 (s, 9H), 1.46 (s, 9H), 2.59 (dd, 
1H, J1 = 6.3 and J2 = 16.5 Hz), 2.76 (dd, 1H, J1 = 7.3 and J2 = 16.5 Hz), 3.50 (dd, 1H, 
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J1 = 7.2 and J2 = 9.4 Hz), 3.73 (dd, 1H, J1 = 6.7 Hz and J2 = 9.4 Hz), 4.51 (s, 2H), 
4.61 (m, 1H), 7.31-7.34 (m, 5H), 9.75 (s, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ –
4.5, 18.1, 26.0, 28.3, 43.8, 57.8, 68.5, 73.0, 82.0, 127.4, 128.5, 131.8, 137.9, 158.6, 
199.9 ppm; HRMS calculated for (C22H37NO5Si) requires m/z [M+Na] 446.2339, 
found m/z 446.2343. [α]25D = +1.80 (c = 0.500, CHCl3). 
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14a  
tert-Butyl tert-Butyldimethylsilyloxy((4S)-6-hydroxy-8-phenyloct-7-yn-4-
yl)carbamate (14a): Phenylacetylene (0.371 mL, 3.31 mmol, 1.50 equiv) was 
dissolved in dry THF (1 mL) and cooled to -78 °C. A solution of n-butyllithium (1.15 
mL, 2.50 M in hexanes, 1.30 equiv) was then added drop wise. The mixture was 
stirred for 30 min at -78 °C and then 15a (760 mg, 2.19 mmol, 1.00 equiv) was 
slowly added. The mixture was stirred for 4-5 h. When the reaction was complete as 
indicated by TLC, the mixture was quenched by adding aqueous saturated solution of 
ammonium chloride. The aqueous layer was separated and extracted three times with 
ethyl ether. The organic layers were combined, washed with water then with brine, 
dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. 
Purification by silica gel column chromatography (20% Et2O/hexane) provided the 
title compound as pale yellow oil (631 mg, 64%). IR (thin film) 3350, 3028, 2925, 
1708, 1600, 1384, 1364, 1158 758, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.19 (s, 
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3H), 0.20 (s, 3H), 0.95 (m, 12H), 1.28-1.44 (m, 3H), 1.47 (s, 9H), 1.62-1.76 (m, 1H), 
1.77-1.91 (m, 1H), 2.19-2.34 (m, 1H), 2.84 (br s, 1H), 3.96-4.10 (br m, 1H), 4.69 (m, 
1H), 7.28-7.30 (m, 3H), 7.41-7.44 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ –4.5, 
13.9, 18.1, 19.9, 26.0, 28.2, 31.6, 40.6, 60.2, 61.5, 81.5, 84.7, 89.9, 122.8, 128.2, 
131.7, 158.1 ppm; HRMS calculated for (C25H41NO4Si) requires m/z [M+Na] 
470.2703, found m/z 470.2692. 
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tert-Butyl tert-Butyldimethylsilyloxy((4S)-6-hydroxy-8-(4-methoxyphenyl)oct-7-
yn-4-yl)carbamate (14b): 4-Ethynylanisole (0.291 mL, 2.17 mmol, 1.50 equiv) was 
dissolved in dry THF (1 mL) and cooled to -78 °C. A solution of n-butyllithium (0.75 
mL, 2.5 M in hexanes, 1.3 equiv) was then added drop wise. The mixture was stirred 
for 30 min at -78 °C and then 15a (500 mg, 1.45 mmol, 1.00 equiv) was slowly 
added. The mixture was stirred for 4-5 h. When the reaction was complete as 
indicated by TLC, the mixture was quenched by adding aqueous saturated solution of 
ammonium chloride. The aqueous layer was separated and extracted three times with 
ethyl ether. The organic layers were combined, washed with water then with brine, 
dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. 
Purification by silica gel column chromatography (20% Et2O/hexane) provided the 
title compound as pale yellow oil (240 mg, 33%). IR (thin film) 3348, 2925, 2858, 
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1708, 1598, 1384, 1364,1177, 835 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.18 (s, 3H), 
0.19 (s, 3H), 0.90-0.95 (m, 12H), 1.36-1.40 (m, 3H), 1.45 (s, 4H), 1.47 (s, 5H), 1.74-
1.88 (m, 2H), 1.73-1.88 (m, 2H), 2.16-2.32 (m, 1H), 2.87 (br s, 1H), 3.79 (s, 3H), 
3.97-4.09 (br m, 1H), 4.66 (m, 1H), 6.81 (d, 2H, J = 6.8 Hz), 7.36 (d, 2H, J = 6.8 Hz) 
ppm; 13C NMR (100 MHz, CDCl3) δ –4.5, 13.9, 18.1, 19.9, 26.1, 28.3, 35.6, 40.7, 
55.2, 60.2, 61.5, 81.6, 84.4, 88.6, 113.9, 114.9, 133.2, 158.3, 159.6 ppm; HRMS 
calculated for (C25H41NO4Si) requires m/z [M+Na] 500.2808, found m/z 500.2799. 
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tert-Butyl tert-Butyldimethylsilyloxy((4S)-6-hydroxy-8-(4-
(trifluoromethyl)phenyl)oct-7-yn-4-yl)carbamate (14c): 4-Ethynyl-α,α,α-
trifluorotoluene (0.366 mL, 2.17 mmol, 1.50 equiv) was dissolved in dry THF (1 mL) 
and cooled to -78 °C. A solution of n-butyllithium (1.18 mL, 1.60 M in hexanes, 1.30 
equiv) was then added drop wise. The mixture was stirred for 30 min at -78 °C and 
then 15a (500 mg, 1.45 mmol, 1.00 equiv) was slowly added. The mixture was stirred 
for 4-5 h. When the reaction was complete as indicated by TLC, the mixture was 
quenched by adding aqueous saturated solution of ammonium chloride. The aqueous 
layer was separated and extracted three times with ethyl ether. The organic layers 
were combined, washed with water then with brine, dried over anhydrous magnesium 
sulfate, filtered and concentrated in vacuo. Purification by silica gel column 
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chromatography (20% Et2O/hexane) provided the title compound as pale yellow oil 
(617 mg, 83%). IR (thin film) 3252, 2925, 2854, 1710, 1458, 1383, 1364, 1168, 875 
cm-1; 1H NMR (400 MHz, CDCl3) δ 0.17 (s, 3H), 0.19 (s, 3H), 0.91-0.94 (m, 3H), 
0.96(s, 9H), 1.45-1.49 (m, 12H), 1.75-1.92 (m, 2H), 2.19-2.35 (m, 1H), 3.74 (br s, 
1H), 3.94-4.09 (br m, 1H), 4.70 (m, 1H), 7.52-7.56 (m, 4H) ppm; 13C NMR (100 
MHz, CDCl3) δ –4.4, 13.9, 18.1, 19.9, 26.0, 28.2, 35.7, 39.8, 60.1, 61.4, 81.6, 83.2, 
92.4, 122.6, 125.2, 126.7, 130.2, 131.9, 158.4 ppm; HRMS calculated for 
(C25H41NO4Si) requires m/z [M+Na] 538.2576, found m/z 538.2566. 
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tert-Butyl tert-Butyldimethylsilyloxy((4S)-6-hydroxy-8-(thiophen-3-yl)oct-7-yn-4-
yl)carbamate (14d): 3-Ethynylthiophene (0.196 mL, 1.91 mmol, 1.50 equiv) was 
dissolved in dry THF (1 mL) and cooled to -78 °C. A solution of n-butyllithium (1.19 
mL, 1.60 M in hexanes, 1.50 equiv) was then added drop wise. The mixture was 
stirred for 30 min at -78 °C and then 15a (440 mg, 1.27 mmol, 1.00 equiv) was 
slowly added. The mixture was stirred for 4-5 h. When the reaction was complete as 
indicated by TLC, the mixture was quenched by adding aqueous saturated solution of 
ammonium chloride. The aqueous layer was separated and extracted three times with 
ethyl ether. The organic layers were combined, washed with water then with brine, 
dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. 
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Purification by silica gel column chromatography (20% Et2O/hexane) provided the 
title compound as pale yellow oil (149 mg, 26%). IR (thin film) 3258, 2960, 2932, 
1708, 1456, 1383, 1369, 1158, 849 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.18 (s, 6H), 
0.91-0.95 (m, 3H), 0.96 (s, 9H), 1.41-1.46 (m, 3H), 1.48 (s, 9H), 1.79-1.89 (m, 2H), 
2.21-2.23 (m, 1H), 3.57 (br s, 1H), 3.91-4.09 (br m, 1H), 4.65 (m, 1H), 7.08 (d, 1H, J 
= 5.0 Hz) 7.24 (m, 1H), 7.41 (d, 1H, J = 3.0 Hz) ppm; 13C NMR (100 MHz, CDCl3) δ 
–4.5, 13.9, 18.1, 19.9, 26.0, 28.3, 35.6, 39.9, 60.2, 61.5, 79.6, 81.9, 89.4, 121.9, 125.1, 
128.8, 129.9, 158.8 ppm; HRMS calculated for (C25H41NO4Si) requires m/z [M+Na] 
476.2267, found m/z 476.2260. 
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tert-Butyl tert-Butyldimethylsilyloxy((4S)-6-hydroxynon-7-yn-4-yl)carbamate 
(14e): To a solution of 15a (518 mg, 1.50 mmol, 1.00 equiv) in dry THF (30 mL), at -
78 °C, under argon, 1-propynyl magnesium bromide (6.00 mmol, 0.500 M in 
tetrahydrofuran, 4.00 equiv) was slowly added. The reaction mixture was stirred at -
78 °C and monitored by TLC. After 4-5 h when the reaction was complete as 
indicated by TLC, the mixture was quenched by adding aqueous saturated solution of 
ammonium chloride. Then it was diluted with ethyl ether, washed with brine, dried, 
filtered and concentrated in vacuo. Purification by silica gel column chromatography 
(20% Et2O/hexane) provided the title compound as yellow oil. (316.5 mg, 55%). IR 
(thin film) 3212, 2961, 2933, 1709, 1384, 1364, 1142 cm-1; 1H NMR (400 MHz, 
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CDCl3) δ 0.14 (s, 6H), 0.86-0.89 (m, 3H), 0.92 (s, 9H), 1.32-1.38 (m, 3H), 1.44 (s, 
9H), 1.64-1.72 (m, 2H), 1.79 (s, 3H), 2.01-2.16 (m, 1H), 2.75 (s, 1H), 3.87-3.99 (br 
m, 1H), 4.39 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ –4.4, 3.6, 13.7, 18.2, 19.9, 
26.0, 28.3, 35.6, 40.8, 59.8, 61.1, 79.9, 80.6, 81.7, 158.3 ppm; HRMS calculated for 
(C20H39NO4Si) requires m/z [M+Na] 408.2546, found m/z 408.2556. 
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tert-Butyl tert-Butyldimethylsilyloxy((4S)-6-hydroxy-9,9-dimethyldec-7-yn-4-
yl)carbamate (14f): 3,3-Dimethyl-but-1-yn (0.217 mL, 1.73 mmol, 1.80 equiv) was 
dissolved in dry THF (1 mL) and cooled to -78 °C. A solution of n-butyllithium (1.08 
mL, 1.60 M in hexanes, 1.80 equiv) was then added drop wise. The mixture was 
stirred for 30 min at -78 °C and then 15a (331 mg, 0.958 mmol, 1.00 equiv) was 
slowly added. The mixture was stirred for 4-5 h. When the reaction was complete as 
indicated by TLC, the mixture was quenched by adding aqueous saturated solution of 
ammonium chloride. The aqueous layer was separated and extracted three times with 
ethyl ether. The organic layers were combined, washed with water then with brine, 
dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. 
Purification by silica gel column chromatography (15% Et2O/hexane) provided the 
title compound as pale yellow oil (277 mg, 70%). IR (thin film) 3224, 2964, 2934, 
2874, 1709, 1459, 1383, 1369, 1163 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.15 (s, 
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3H), 0.17 (s, 3H), 0.88-0.90 (m, 3H), 0.93 (s, 9H), 1.19 (s, 9H), 1.32-1.41 (m, 3H), 
1.46 (s, 9H), 1.66-1.77 (m, 2H), 2.01-2.20 (m, 1H), 2.55 (br s, 1H), 3.82-3.98 (br m, 
1H), 4.41 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ –4.4, 13.9, 18.1, 19.9, 26.1, 
27.3, 28.2, 31.0, 35.6, 41.2, 59.8, 61.2, 79.8, 81.6, 93.3, 158.3 ppm; HRMS calculated 
for (C20H39NO4Si) requires m/z [M+Na] 450.3016, found m/z 450.3011. 
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tert-Butyl tert-Butyldimethylsilyloxy((2S)-4-hydroxy-6-(4-methoxyphenyl)hex-5-
yn-2-yl)carbamate (14g): 4-Ethynylanisole (0.344 mL, 2.57 mmol, 1.70 equiv) was 
dissolved in dry THF (1 mL) and cooled to -78 °C. A solution of n-butyllithium (1.61 
mL, 1.60 M in hexanes, 1.70 equiv) was then added drop wise. The mixture was 
stirred for 30 min at -78 °C and then 15b (480 mg, 1.51 mmol, 1.00 equiv) was 
slowly added. The mixture was stirred for 4-5 h. When the reaction was complete as 
indicated by TLC, the mixture was quenched by adding aqueous saturated solution of 
ammonium chloride. The aqueous layer was separated and extracted three times with 
ethyl ether. The organic layers were combined, washed with water then with brine, 
dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. 
Purification by silica gel column chromatography (20% Et2O/hexane) provided the 
title compound as pale yellow oil (400 mg, 59%). IR (thin film) 3348, 2928, 1711, 
1598, 1384, 1364, 1177, 840 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.18 (s, 6H), 0.96 
 49 
(s, 9H), 1.31 (d, 3H J = 6.9 Hz), 1.48 (s, 5H), 1.49 (s, 4H), 1.81-1.95 (m, 1H), 2.24-
2.34 (m, 1H), 3.80 (s, 3H), 4.05-4.25(br m, 1H), 4.64 (m, 1H), 6.81 (d, 2H, J = 8.8 
Hz), 7.35 (d, 2H, J = 8.8 Hz) ppm; 13C NMR (100 MHz, CDCl3) δ -4.5, 18.0, 18.5, 
26.0, 28.3, 41.9, 55.2, 60.2, 61.2, 81.6, 84.5, 88.2, 113.8, 114.9, 133.1, 158.4, 159.6 
ppm; HRMS calculated for (C19H25NO4) requires m/z [M+Na] 472.2495, found m/z 
472.2490. 
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tert-Butyl tert-Butyldimethylsilyloxy((2R)-1-(1,3-dioxoisoindolin-2-yl)-4-hydroxy-
6-(4-methoxyphenyl)hex-5-yn-2-yl)carbamate (14h): 4-Ethynylanisole (0.052 mL, 
0.39 mmol, 1.2 equiv) was dissolved in dry THF (10 mL) and cooled to -78 °C. A 
solution of Lithium bis(trimethylsilyl)amide (0.42 mL, 1.0 M in tetrahydrofuran, 1.3 
equiv) was then added drop wise. The mixture was stirred for 30 min at -78 °C and 
then 15c (150 mg, 0.324 mmol, 1.00 equiv) was slowly added. The mixture was 
stirred for 4-5 h. When the reaction was complete as indicated by TLC, the mixture 
was quenched by adding aqueous saturated solution of ammonium chloride. The 
aqueous layer was separated and extracted three times with ethyl ether. The organic 
layers were combined, washed with water then with brine, dried over anhydrous 
magnesium sulfate, filtered and concentrated in vacuo. Purification by silica gel 
column chromatography (20% EtOAc/hexane) provided the title compound as pale 
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yellow oil (40 mg, 21%). IR (thin film) 3352, 2900, 1711, 1667, 1384, 1364,1177, 
825 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.18 (s, 6H), 0.86 (s, 4H), 0.88 (s, 5H), 1.42 
(s, 4H), 1.43 (s, 5H), 1.87-2.02 (m, 1H), 2.40-2.47 (m, 1H), 3.80 (s, 3H), 3.86-4.04 
(m, 1H), 4.09-4.29 (m, 1H), 4.29-4.37 (br m, 1H), 4.75 (m, 1H), 6.80 (d, 2H, J = 8.9 
Hz), 7.31 (d, 2H, J = 8.9 Hz), 7.69 (m, 2H), 7.82 (m, 2H) ppm; 13C NMR (100 MHz, 
CDCl3) δ -4.9, 17.9, 25.8, 28.1, 37.5, 40.5, 55.2, 60.4, 61.4, 82.4, 85.0, 87.9, 113.8, 
123.3, 132.1, 133.1, 133.9, 157.6, 159.5, 168.0 ppm; HRMS calculated for 
(C19H25NO4) requires m/z [M+Na] 617.2659, found m/z 617.2651. 
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tert-Butyl (2R)-1-(Benzyloxy)-4-hydroxy-6-(4-methoxyphenyl)hex-5-yn-2-yl(tert-
butyldimethylsilyloxy)carbamate (14i): 4-Ethynylanisole (0.152 mL, 1.13 mmol, 
1.20 equiv) was dissolved in dry THF (1 mL) and cooled to -78 °C. A solution of n-
butyllithium (1.23 mL, 1.60 M in hexanes, 1.30 equiv) was then added drop wise. The 
mixture was stirred for 30 min at -78 °C and then 15d (400 mg, 0.944 mmol, 1.00 
equiv) was slowly added. The mixture was stirred for 4-5 h. When the reaction was 
complete as indicated by TLC, the mixture was quenched by adding aqueous 
saturated solution of ammonium chloride. The aqueous layer was separated and 
extracted three times with ethyl ether. The organic layers were combined, washed 
with water then with brine, dried over anhydrous magnesium sulfate, filtered and 
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concentrated in vacuo. Purification by silica gel column chromatography (20% 
Et2O/hexane) provided the title compound as pale yellow oil (240 mg, 46%). IR (thin 
film) 3350, 2967, 2900, 2833, 1713, 1384, 1364,1178, 850 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 0.17 (s, 2H), 0.19 (s, 4H), 0.95 (s, 9H), 1.44 (s, 5H), 1.46 (s, 4H), 1.90-2.08 
(m, 1H), 2.19-2.29 (m, 1H), 3.24 (br s, 1H), 3.55-3.66 (m, 1H), 3.75-3.83 (m, 1H), 
3.80 (s, 3H), 4.19-4.35 (m, 1H), 4.54-4.56 (m, 2H), 4.74 (m, 1H), 6.81 (d, 2H, J = 8.8 
Hz), 7.32-7.36 (m, 7H) ppm; 13C NMR (100 MHz, CDCl3) δ -4.6, 18.0, 26.0, 28.2, 
38.1, 55.2, 60.4, 61.2, 71.0, 73.0, 81.8, 84.7, 88.2, 113.8, 114.9, 125.9, 127.6, 128.3, 
133.1, 137.9, 158.5, 159.6 ppm; HRMS calculated for (C19H25NO4) requires m/z 
[M+Na] 578.2914, found m/z 578.2909. 
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(S)-tert-Butyl tert-Butyldimethylsilyloxy(6-oxo-8-phenyloct-7-yn-4-yl)carbamate 
(13a): Compound 14a (0.622 g, 1.39 mmol, 1.00 equiv) was dissolved in 1,2-
dichloroethane (37 mL) and activated MnO2 (3.07 g, 41.7 mmol, 30.0 equiv) was 
added. The reaction mixture was refluxed overnight. After completion as indicated by 
TLC, the reaction mixture was filtered through a pad of celite. The solution was 
concentrated in vacuo to give the title compound as a crude pale yellow oil (432 mg, 
70%). IR (thin film) 3069, 3026, 2203, 1690, 1384, 1364, 1158, 758, 698 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 0.17 (s, 3H), 0.18 (s, 3H), 0.92-0.95 (m, 3H), 0.96 (s, 9H), 
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1.36-1.45 (m, 3H), 1.48 (s, 9H), 1.78 (m, 1H), 2.79 (dd, 1H, J1 = 6.9 and J2 = 16.3 
Hz), 3.09 (dd, 1H, J1 = 6.6 and J2 = 16.3 Hz), 4.46 (m, 1H), 7.36-7.40 (m, 2H), 7.43-
7.47 (m, 1H), 7.56-7.58 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ -4.4, 13.9, 
18.2, 19.7, 26.0, 28.2, 34.8, 48.5, 58.9, 81.4, 88.0, 90.8, 120.0, 128.6, 130.7, 133.0, 
158.5, 185.5 ppm; HRMS calculated for (C19H25NO4) requires m/z [M+Na] 468.2546, 
found m/z 468.2540. 
 
Boc
N
OTBS
n-Pr
O
13b
OMe  
(S)-tert-Butyl tert-Butyldimethylsilyloxy(8-(4-methoxyphenyl)-6-oxooct-7-yn-4-
yl)carbamate (13b): Compound 14b (0.240 g, 0.50 mmol, 1.00 equiv) was dissolved 
in 1,2-dichloroethane (15 mL) and activated MnO2 (1.54 g, 15.1 mmol, 30.0 equiv) 
was added. The reaction mixture was refluxed overnight. After completion as 
indicated by TLC, the reaction mixture was filtered through a pad of celite. The 
solution was concentrated in vacuo to give the title compound as a crude pale yellow 
oil (162 mg, 68%). IR (thin film) 2925, 2858, 2208, 1680, 1458, 1384, 1364, 1177, 
841 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.16 (s, 3H), 0.17 (s, 3H), 0.91-0.94 (m, 
3H), 0.96 (s, 9H), 1.35-1.44 (m, 3H), 1.47 (s, 9H), 1.77 (m, 1H), 2.78 (dd, 1H, J1 = 
7.1 and J2 = 16.2 Hz), 3.07 (dd, 1H, J1 = 6.4 and J2 = 16.2 Hz), 3.84 (s, 3H), 4.46 (m, 
1H), 6.89 (d, 2H, J = 6.8 Hz), 7.52 (d, 2H, J = 6.8 Hz) ppm; 13C NMR (100 MHz, 
CDCl3) δ -5.4, 12.8, 17.2, 18.6, 25.1, 27.1, 33.7, 47.5, 54.4, 58.0, 80.3, 86.9, 91.0, 
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110.8, 113.3, 133.9, 157.4, 160.6, 184.4 ppm; HRMS calculated for (C19H25NO4) 
requires m/z [M+Na] 498.2652, found m/z 498.2644. 
 
Boc
N
OTBS
n-Pr
O
13c
CF3  
(S)-tert-Butyl tert-Butyldimethylsilyloxy(6-oxo-8-(4-(trifluoromethyl)phenyl)oct-
7-yn-4-yl)carbamate (13c): Compound 14c (0.151 g, 0.294 mmol, 1.00 equiv) was 
dissolved in 1,2-dichloroethane (10 mL) and activated MnO2 (0.901 g, 8.81 mmol, 
30.0 equiv) was added. The reaction mixture was refluxed overnight. After 
completion as indicated by TLC, the reaction mixture was filtered through a pad of 
celite. The solution was concentrated in vacuo to give the title compound as a crude 
pale yellow oil (136 mg, 90%). IR (thin film) 2925, 2854, 2204, 1695, 1458, 1384, 
1364, 1168, 875 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.17 (s, 3H), 0.18 (s, 3H), 0.87-
0.93 (m, 3H), 0.95 (s, 9H), 1.39-1.44 (m, 3H), 1.47 (s, 9H), 1.64 (br s, 1H), 1.77 (m, 
1H), 2.78 (dd, 1H, J1 = 6.5 and J2 = 16.3 Hz), 3.11 (dd, 1H, J1 = 7.0 and J2 = 16.3 
Hz), 4.46 (m, 1H), 7.62-7.68 (m, 4H) ppm; 13C NMR (100 MHz, CDCl3) δ -5.4, 12.8, 
17.2, 18.6, 25.1, 27.2, 33.8, 47.4, 57.8, 80.5, 87.1, 88.2, 122.9, 124.5, 124.6, 131.9, 
132.1, 157.5, 184.1 ppm; HRMS calculated for (C19H25NO4) requires m/z [M+Na] 
536.2420, found m/z 536.2411. 
 
 54 
Boc
N
OTBS
n-Pr
O
13d S  
(S)-tert-Butyl tert-Butyldimethylsilyloxy(6-oxo-8-(thiophen-3-yl)oct-7-yn-4-
yl)carbamate (13d): Compound 14d (0.161 g, 0.355 mmol, 1.00 equiv) was 
dissolved in 1,2-dichloroethane (10 mL) and activated MnO2 (1.09 g, 10.7 mmol, 
30.0 equiv) was added. The reaction mixture was refluxed overnight. After 
completion as indicated by TLC, the reaction mixture was filtered through a pad of 
celite. The solution was concentrated in vacuo to give the title compound as a crude 
pale yellow oil (160 mg, 100%). IR (thin film) 2960, 2932, 2205, 1689, 1456, 1383, 
1369, 1158, 849 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.16 (s, 3H), 0.17 (s, 3H), 0.91-
0.94 (m, 3H), 0.95 (s, 9H), 1.35-1.44 (m, 3H), 1.47 (s, 9H), 1.76 (m, 1H), 2.77 (dd, 
1H, J1 = 7.2 and J2 = 16.7 Hz), 3.07 (dd, 1H, J1 = 6.5 and J2 = 16.4 Hz), 4.44 (m, 1H), 
7.21 (d, 1H, J = 4.9 Hz) 7.32 (s, 1H), 7.74 (d, 1H, J = 2.9 Hz) ppm; 13C NMR (100 
MHz, CDCl3) δ -5.4, 12.8, 17.2, 18.6, 25.1, 27.2, 33.7, 47.4, 57.9, 80.4, 85.2, 87.2, 
118.3, 125.1, 129.2, 132.8, 157.4, 184.4 ppm; HRMS calculated for (C19H25NO4) 
requires m/z [M+Na] 474.2110, found m/z 474.2101. 
 
Boc
N
OTBS
n-Pr
O
Me
13e  
(S)-tert-Butyl tert-Butyldimethylsilyloxy(6-oxonon-7-yn-4-yl)carbamate (13e): 
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Compound 14e (0.317 g, 0.821 mmol, 1.00 equiv) was dissolved in 1,2-
dichloroethane (23 mL) and activated MnO2 (2.52 g, 24.6 mmol, 30.0 equiv) was 
added. The reaction mixture was refluxed overnight. After completion as indicated by 
TLC, the reaction mixture was filtered through a pad of celite. The solution was 
concentrated in vacuo to give the title compound as a crude pale yellow oil (242 mg, 
77%). IR (thin film) 2961, 2933, 2216, 1670, 1384, 1364, 1142 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.13 (s, 3H), 0.14 (s, 3H), 0.87-0.91 (m, 3H), 0.93 (s, 9H), 1.31-1.41 
(m, 3H), 1.46 (s, 9H), 1.72 (m, 1H), 1.99 (s, 3H), 2.62 (dd, 1H, J1 = 7.0 and J2 = 16.2 
Hz), 2.92 (dd, 1H, J1 = 6.4 and J2 = 16.2 Hz), 4.36 (m, 1H) ppm; 13C NMR (100 
MHz, CDCl3) δ -4.4, 13.8, 18.0, 19.6, 26.0, 28.2, 34.7, 48.5, 58.8, 80.4, 81.3, 90.2, 
158.4, 185.6 ppm; HRMS calculated for (C19H25NO4) requires m/z [M+Na] 406.2390, 
found m/z 406.2383. 
 
Boc
N
OTBS
n-Pr
O
13f  
(S)-tert-Butyl tert-Butyldimethylsilyloxy(9,9-dimethyl-6-oxodec-7-yn-4-
yl)carbamate (13f): Compound 14f (0.277 g, 0.648 mmol, 1.00 equiv) was dissolved 
in 1,2-dichloroethane (15 mL) and activated MnO2 (1.99 g, 19.4 mmol, 30.0 equiv) 
was added. The reaction mixture was refluxed overnight. After completion as 
indicated by TLC, the reaction mixture was filtered through a pad of celite. The 
solution was concentrated in vacuo to give the title compound as a crude pale yellow 
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oil (249 mg, 90%). IR (thin film) 2964, 2934, 2874, 2220, 1698, 1459, 1383, 1369, 
1163 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.14 (s, 3H), 0.16 (s, 3H), 0.89-0.94 (m, 
3H), 0.95 (s, 9H), 1.27 (s, 9H), 1.30-1.44 (m, 3H), 1.48 (s, 9H), 1.75 (m, 1H), 2.66 
(dd, 1H, J1 = 7.2 and J2 = 16.4 Hz), 2.95 (dd, 1H, J1 = 6.2 and J2 = 16.4 Hz), 4.35 (m, 
1H) ppm; 13C NMR (100 MHz, CDCl3) δ -4.5, 13.8, 18.2, 19.6, 26.0, 27.7, 28.2, 30.0, 
34.6, 48.6, 58.8, 79.5, 81.3, 101.5, 158.4, 185.7 ppm; HRMS calculated for 
(C19H25NO4) requires m/z [M+Na] 448.2859, found m/z 448.2852. 
 
Boc
N
OTBS
Me
O
13g
OMe  
(S)-tert-Butyl tert-Butyldimethylsilyloxy(6-(4-methoxyphenyl)-4-oxohex-5-yn-2-
yl)carbamate (13g): Compound 14g (0.400 g, 0.889 mmol, 1.00 equiv) was 
dissolved in 1,2-dichloroethane (25 mL) and activated MnO2 (2.73 g, 26.7 mmol, 
30.0 equiv) was added. The reaction mixture was refluxed overnight. After 
completion as indicated by TLC, the reaction mixture was filtered through a pad of 
celite. The solution was concentrated in vacuo to give the title compound as a crude 
pale yellow oil (213 mg, 54%). IR (thin film) 2928, 2208, 1682, 1384, 1364, 1177, 
840 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.16 (s, 6H), 0.96 (s, 9H), 1.28 (d, 3H J = 
6.7 Hz), 1.48 (s, 9H), 2.88 (dd, 1H, J1 = 8.5 and J2 = 16.1 Hz), 3.04 (dd, 1H, J1 = 5.1 
and J2 = 16.1 Hz), 3.83 (s, 3H), 4.46 (m, 1H), 6.88 (d, 2H, J = 8.8 Hz), 7.52 (d, 2H, J 
= 8.8 Hz) ppm; 13C NMR (100 MHz, CDCl3) δ -5.5, 16.5, 17.1, 25.1, 27.1, 48.4, 54.4, 
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58.0, 80.6, 86.9, 91.2, 110.7, 113.3, 134.2, 157.5, 160.7, 184.3 ppm; HRMS 
calculated for (C19H25NO4) requires m/z [M+Na] 470.2339, found m/z 470.2333. 
 
13h
Boc
N
OTBS
N
O
OMe
O
O
 
(R)-tert-Butyl tert-Butyldimethylsilyloxy(1-(1,3-dioxoisoindolin-2-yl)-6-(4-
methoxyphenyl)-4-oxohex-5-yn-2-yl)carbamate (13h): Compound 14h (40. mg, 
0.067 mmol, 1.0 equiv) was dissolved in 1,2-dichloroethane (10 mL) and activated 
MnO2 (0.206 g, 2.02 mmol, 30.0 equiv) was added. The reaction mixture was 
refluxed overnight. After completion as indicated by TLC, the reaction mixture was 
filtered through a pad of celite. The solution was concentrated in vacuo to give the 
title compound as a crude pale yellow oil (40 mg, 100%). IR (thin film) 2900, 2206, 
1686, 1450, 1384, 1364, 1177, 825 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.16 (s, 3H), 
0.19 (s, 3H), 0.88 (s, 9H), 1.46 (s, 9H), 2.97 (dd, 1H, J1 = 6.5 and J2 = 16.8 Hz), 3.25 
(dd, 1H, J1 = 6.8 and J2 = 16.8 Hz), 3.85 (s, 3H), 3.90 (dd, 1H, J1 = 6.8 and J2 = 13.6 
Hz), 4.14 (dd, 1H, J1 = 7.2 and J2 = 13.6 Hz), 4.79 (m, 1H), 6.89 (d, 2H, J = 8.8 Hz), 
7.52 (d, 2H, J = 8.8 Hz), 7.68 (m, 2H), 7.81 (m, 2H) ppm; 13C NMR (100 MHz, 
CDCl3) δ -5.8, 17.0, 24.9, 27.1, 38.0, 45.4, 54.4, 56.7, 81.0, 86.6, 91.8, 110.6, 113.3, 
122.2, 131.1, 132.8, 134.2, 156.6, 160.7, 166.9, 183.0 ppm; HRMS calculated for 
(C19H25NO4) requires m/z [M+Na] 615.2502, found m/z 615.2493. 
 
 58 
Boc
N
OTBS
O
13i
OMe
BnO
 
(R)-tert-Butyl 1-(Benzyloxy)-6-(4-methoxyphenyl)-4-oxohex-5-yn-2-yl(tert-
butyldimethylsilyloxy)carbamate (13i): Compound 14i (0.240 g, 0.432 mmol, 1.00 
equiv) was dissolved in 1,2-dichloroethane (15 mL) and activated MnO2 (1.29 g, 12.6 
mmol, 30.0 equiv) was added. The reaction mixture was refluxed overnight. After 
completion as indicated by TLC, the reaction mixture was filtered through a pad of 
celite. The solution was concentrated in vacuo to give the title compound as a crude 
pale yellow oil (210 mg, 88%). IR (thin film) 2967, 2900, 2833, 2203, 1685, 1384, 
1364, 1178, 850 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.10 (s, 6H), 0.88 (s, 9H), 1.38 
(s, 9H), 2.76 (dd, 1H, J1 = 6.9 and J2 = 16.3 Hz), 2.95 (dd, 1H, J1 = 6.7 and J2 = 16.3 
Hz), 3.44 (dd, 1H, J1 = 6.5 and J2 = 9.7 Hz), 3.67 (dd, 1H, J1 = 7.4 and J2 = 9.7 Hz), 
3.75 (s, 3H), 4.46 (s, 2H), 4.74 (m, 1H), 6.80 (d, 2H, J = 8.8 Hz), 7.17-7.27 (m, 5H), 
7.44 (d, 2H, J = 8.8 Hz) ppm; 13C NMR (100 MHz, CDCl3) δ -5.5, 17.1, 25.2, 27.2, 
44.4, 54.4, 57.5, 68.3, 71.9, 80.7, 86.8, 91.4, 110.7, 113.3, 126.5, 126.6, 127.3, 133.4, 
137.2, 157.6, 160.6, 183.7 ppm; HRMS calculated for (C19H25NO4) requires m/z 
[M+Na] 576.2757, found m/z 576.2751. 
 
 59 
20a
N O
O
Boc
n-Pr
 
(S)-tert-Butyl 5-Oxo-7-phenyl-3-propyl-4,5-dihydro-1,2-oxazepine-2(3H)-
carboxylate (20a): Compound 13a (0.304 g, 0.682 mmol, 1.00 equiv) was dissolved 
in THF (24 mL). Tetrabutylammonium fluoride (1.71 mmol, 1.00 M in 
tetrahydrofuran, 2.50 equiv) was added at room temperature to the above solution. 
The reaction mixture was allowed to stir for 1 min. After 1 min, when reaction was 
complete as indicated by TLC, the reaction mixture was quenched by silica gel, 
concentrated in vacuo. Purification by silica gel column chromatography (25% 
Et2O/hexane) provided the title compound as yellow oil (173 mg, 77%). IR (thin film) 
3402, 3069, 3026, 2925, 1710, 1664, 1619, 1493, 1452, 1384, 1367, 1158, 759, 699 
cm-1. 1H NMR (400 MHz, CDCl3) δ 0.96 (t, 3H, J = 7.3 Hz), 1.40 (m, 2H), 1.49 (s, 
9H), 1.69 (m, 1H), 1.83 (m, 1H), 2.88-2.92 (m, 2H), 4.59 (m, 1H), 5.89 (s, 1H), 7.40-
7.50 (m, 3H), 7.91 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 13.7, 19.0, 28.1, 
35.3, 47.5, 58.4, 83.2, 108.3, 128.1, 128.7, 129.1, 132.0, 153.3, 173.7, 198.1 ppm; 
HRMS calculated for (C19H25NO4) requires m/z [M+Na] 354.1682, found m/z 
354.1680. [α]25D = -2.40 (c = 0.500, CHCl3). 
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20b
N O
O
Boc
n-Pr
OMe
 
(S)-tert-Butyl 7-(4-Methoxyphenyl)-5-oxo-3-propyl-4,5-dihydro-1,2-oxazepine-
2(3H)-carboxylate (20b): Compound 13b (0.162 g, 0.340 mmol, 1.00 equiv) was 
dissolved in THF (12 mL). Tetrabutylammonium fluoride (0.851 mmol, 1.00 M in 
tetrahydrofuran, 2.50 equiv) was added at room temperature to the above solution. 
The reaction mixture was allowed to stir for 1 min. After 1 min, when reaction was 
complete as indicated by TLC, the reaction mixture was quenched by silica gel, 
concentrated in vacuo. Purification by silica gel column chromatography (20% 
Et2O/hexane) provided the title compound as yellow oil (112 mg, 91%). IR (thin film) 
3400, 2961, 2933, 1709, 1659, 1604, 1510, 1458, 1384, 1369, 1332, 1256, 1177, 841 
cm-1. 1H NMR (400 MHz, CDCl3) δ 0.93 (t, 3H, J = 7.3 Hz), 1.36 (m, 2H), 1.46 (s, 
9H), 1.67 (m, 1H), 1.76 (m, 1H), 2.81-2.91 (m, 2H), 3.82 (s, 3H), 4.54 (m, 1H), 5.76 
(s, 1H), 6.90 (d, 2H, J = 9 Hz), 7.84 (d, 2H, J = 8.9 Hz) ppm; 13C NMR (100 MHz, 
CDCl3) δ 13.8, 18.9, 28.0, 35.4, 47.1, 55.5, 58.4, 82.9, 106.8, 114.0, 124.3, 129.8, 
153.2, 162.6, 174.0, 197.9 ppm; HRMS calculated for (C20H27NO5) requires m/z 
[M+Na] 384.1787, found m/z 384.1782. [α]25D = -6.20 (c = 0.500, CHCl3). 
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20c
N O
O
Boc
n-Pr
CF3
 
(S)-tert-Butyl 5-Oxo-3-propyl-7-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1,2-
oxazepine-2(3H)-carboxylate (20c): Compound 13c (0.108 g, 0.210 mmol, 1.00 
equiv) was dissolved in THF (7 mL). Tetrabutylammonium fluoride (0.63 mmol, 1.0 
M in tetrahydrofuran, 3.0 equiv) was added at room temperature to the above 
solution. The reaction mixture was allowed to stir for 1 min. After 1 min, when 
reaction was complete as indicated by TLC, the reaction mixture was quenched by 
silica gel, concentrated in vacuo. Purification by silica gel column chromatography 
(20% Et2O/hexane) provided the title compound as yellow oil (19.5 mg, 23%). IR 
(thin film) 3400, 2925, 2854, 1737, 1683, 1650, 1459, 1384, 1364, 1324, 1246, 1169, 
875 cm-1. 1H NMR (400 MHz, CDCl3) δ 0.97 (t, 3H, J = 7.3 Hz), 1.40 (m, 2H), 1.50 
(s, 9H), 1.62-1.74 (m, 1H), 1.78-1.87 (m, 1H), 2.92 (m, 2H), 4.59 (m, 1H), 5.95 (s, 
1H), 7.68 (d, 2H, J = 8.3 Hz), 8.04 (d, 2H, J = 8.2 Hz) ppm; 13C NMR (100 MHz, 
CDCl3) δ 13.8, 18.9, 28.1, 35.0, 47.4, 58.5, 83.4, 109.9, 122.4, 125.5, 128.1, 132.9, 
135.4, 153.2, 171.7, 197.7 ppm; HRMS calculated for (C20H24F3NO4) requires m/z 
[M+Na] 422.1555, found m/z 422.1553. [α]25D = +3.00 (c = 0.500, CHCl3). 
 
 62 
20d
N O
O
Boc
n-Pr S
 
(S)-tert-Butyl 5-Oxo-3-propyl-7-(thiophen-3-yl)-4,5-dihydro-1,2-oxazepine-
2(3H)-carboxylate (20d): Compound 13d (0.095 g, 0.209 mmol, 1.00 equiv) was 
dissolved in THF (7 mL). Tetrabutylammonium fluoride (0.628 mmol, 1.00 M in 
tetrahydrofuran, 3.00 equiv) was added at room temperature to the above solution. 
The reaction mixture was allowed to stir for 1 min. After 1 min, when reaction was 
complete as indicated by TLC, the reaction mixture was quenched by silica gel, 
concentrated in vacuo. Purification by silica gel column chromatography (20% 
Et2O/hexane) provided the title compound as yellow oil (45.4 mg, 64%). IR (thin 
film) 3401, 2961, 2931, 1709, 1662, 1618, 1457, 1383, 1369, 1254, 1158, 1088, 849 
cm-1. 1H NMR (400 MHz, CDCl3) δ 0.96 (t, 3H, J = 7.3 Hz), 1.38-1.43 (m, 2H), 1.47 
(s, 9H), 1.62-1.72 (m, 1H), 1.77-1.86 (m, 1H), 2.91 (m, 2H), 4.54 (m, 1H), 5.81 (s, 
1H), 7.31-7.36 (m, 2H), 8.07 (s, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 13.8, 18.9, 
28.1, 35.4, 47.3, 58.0, 82.9, 107.9, 125.8, 126.8, 126.9, 134.3, 153.1, 168.9, 197.9 
ppm; HRMS calculated for (C17H23NO4S) requires m/z [M+Na] 360.1246, found m/z 
360.1237. [α]25D = -1.80 (c = 0.500, CHCl3). 
 
 63 
N O
O
Me
Boc
20e
n-Pr
 
(S)-tert-Butyl 7-Methyl-5-oxo-3-propyl-4,5-dihydro-1,2-oxazepine-2(3H)-
carboxylate (20e): Compound 13e (0.117 g, 0.305 mmol, 1.00 equiv) was dissolved 
in THF (11 mL). Tetrabutylammonium fluoride (0.763 mmol, 1.00 M in 
tetrahydrofuran, 2.50 equiv) was added at room temperature to the above solution. 
The reaction mixture was allowed to stir for 1 min. After 1 min, when reaction was 
complete as indicated by TLC, the reaction mixture was quenched by silica gel, 
concentrated in vacuo. Purification by silica gel column chromatography (20% 
Et2O/hexane) provided the title compound as yellow oil (60.1 mg, 73%). IR (thin 
film) 3400, 2962, 2933, 1710, 1667, 1384, 1365, 1254, 1142 cm-1. 1H NMR (400 
MHz, CDCl3) δ 0.94 (t, 3H, J = 7.3 Hz), 1.38 (m, 2H), 1.47 (s, 9H), 1.66-1.88 (m, 
2H), 2.11 (s, 3H), 2.81 (m, 2H), 4.42 (m, 1H), 5.31 (s, 1H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 13.7, 19.1, 19.9, 28.0, 35.1, 47.4, 56.7, 82.6, 110.2, 152.6, 173.9, 197.6 
ppm; HRMS calculated for (C14H23NO4) requires m/z [M+Na] 292.1525, found m/z 
292.1512. [α]25D = +5.80 (c = 0.500, CHCl3). 
 
 
 64 
N O
O
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20f
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(S)-tert-Butyl 7-tert-Butyl-5-oxo-3-propyl-4,5-dihydro-1,2-oxazepine-2(3H)-
carboxylate (20f): Compound 13f (0.138 g, 0.325 mmol, 1.00 equiv) was dissolved 
in THF (11 mL). Tetrabutylammonium fluoride (1.29 mmol, 1.00 M in 
tetrahydrofuran, 4.00 equiv) was added at room temperature to the above solution. 
The reaction mixture was allowed to stir for 1 min. After 1 min, when reaction was 
complete as indicated by TLC, the reaction mixture was quenched by silica gel, 
concentrated in vacuo. Purification by silica gel column chromatography (10% 
Et2O/hexane) provided the title compound as yellow oil (52.4 mg, 52%). IR (thin 
film) 3402, 2964, 2934, 2874, 1739, 1710, 1628, 1459, 1383, 1369, 1318, 1255, 1163 
cm-1. 1H NMR (400 MHz, CDCl3) δ 0.94 (t, 3H, J = 7.3 Hz), 1.24 (s, 9H), 1.37 (m, 
2H), 1.56-1.63 (m, 1H), 1.73-1.82 (m, 1H), 2.72 (dd, 1H, J1 = 7.8 and J2 = 14.9 Hz), 
2.87 (dd, 1H, J1 = 7.2 and J2 = 11.5 Hz), 4.46 (m, 1H), 5.33 (s, 1H) ppm; 13C NMR 
(100 MHz, CDCl3) δ 13.7, 19.2, 28.2, 34.4, 47.1, 57.1, 82.8, 105.5, 153.3, 181.9, 
199.1 ppm; HRMS calculated for (C17H29NO4) requires m/z [M+Na] 334.1995, found 
m/z 334.1988. [α]25D = +14.2 (c = 0.500, CHCl3). 
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(S)-tert-Butyl 7-(4-Methoxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1,2-oxazepine-
2(3H)-carboxylate (20g): Compound 13g (0.213 g, 0.476 mmol, 1.00 equiv) was 
dissolved in THF (15 mL). Tetrabutylammonium fluoride (1.43 mmol, 1.00 M in 
tetrahydrofuran, 3.00 equiv) was added at room temperature to the above solution. 
The reaction mixture was allowed to stir for 1 min. After 1 min, when reaction was 
complete as indicated by TLC, the reaction mixture was quenched by silica gel, 
concentrated in vacuo. Purification by silica gel column chromatography (20% 
Et2O/hexane) provided the title compound as yellow oil (70 mg, 44%). IR (thin film) 
3401, 2928, 1711, 1658, 1604, 1452, 1384, 1364, 1257, 1177, 840 cm-1. 1H NMR 
(400 MHz, CDCl3) δ 1.37 (d, 3H, J = 6.3 Hz), 1.52 (s, 9H), 2.79 (m, 1H), 2.87 (m, 
1H), 3.86 (s, 3H), 4.63 (m, 1H), 5.82 (s, 1H), 6.93 (d, 2H, J = 9 Hz), 7.89 (d, 2H, J = 
9 Hz) ppm; 13C NMR (100 MHz, CDCl3) δ 17.8, 28.9, 48.7, 55.4, 55.6, 83.1, 107.2, 
114.3, 124.3, 129.8, 153.6, 162.6, 174.4, 197.8 ppm; HRMS calculated for 
(C18H23NO5) requires m/z [M+Na] 356.1474, found m/z 356.1263. [α]25D = -7.00 (c = 
0.500, CHCl3). 
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(R)-tert-Butyl 3-((1,3-Dioxoisoindolin-2-yl)methyl)-7-(4-methoxyphenyl)-5-oxo-
4,5-dihydro-1,2-oxazepine-2(3H)-carboxylate (20h): Compound 13h (39.9 mg, 
0.0672 mmol, 1.00 equiv) was dissolved in THF (4 mL). Tetrabutylammonium 
fluoride (0.202 mmol, 1.00 M in tetrahydrofuran, 3.00 equiv) was added at room 
temperature to the above solution. The reaction mixture was allowed to stir for 1 min. 
After 1 min, when reaction was complete as indicated by TLC, the reaction mixture 
was quenched by silica gel, concentrated in vacuo. Purification by silica gel column 
chromatography (30% EtOAc/hexane) provided the title compound as yellow oil 
(13.7 mg, 43%). IR (thin film) 3400, 2900, 1718, 1667, 1603, 1450, 1384, 1364, 
1256, 1177, 826 cm-1. 1H NMR (400 MHz, CDCl3) δ 1.31 (s, 9H), 2.87 (m, 1H), 3.0 
(m, 1H), 3.86 (s, 3H), 3.88 (m, 1H), 4.10 (m, 1H), 4.99 (m, 1H), 5.83 (s, 1H), 6.93 (d, 
2H, J = 8.9 Hz), 7.72 (m, 2H), 7.87 (m, 4H) ppm; 13C NMR (100 MHz, CDCl3) δ 
28.0, 39.1, 44.8, 55.4, 56.8, 83.4, 106.7, 114.1, 123.5, 123.9, 129.9, 132.1, 134.2, 
152.5, 162.8, 167.9, 175.0, 196.2 ppm; HRMS calculated for (C26H26N2O7) requires 
m/z [M+Na] 501.1638, found m/z 501.1632. [α]25D = -80.6 (c = 0.500, CHCl3). 
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(R)-tert-Butyl 3-(Benzyloxymethyl)-7-(4-methoxyphenyl)-5-oxo-4,5-dihydro-1,2-
oxazepine-2(3H)-carboxylate (20i): Compound 13i (0.210 g, 0.379 mmol, 1.00 
equiv) was dissolved in THF (9 mL). Tetrabutylammonium fluoride (1.14 mmol, 1.00 
M in tetrahydrofuran, 3.00 equiv) was added at room temperature to the above 
solution. The reaction mixture was allowed to stir for 1 min. After 1 min, when 
reaction was complete as indicated by TLC, the reaction mixture was quenched by 
silica gel, concentrated in vacuo. Purification by silica gel column chromatography 
(20% Et2O/hexane) provided the title compound as yellow oil (80 mg, 48%). IR (thin 
film) 3400, 2967, 2900, 2833, 1750, 1733, 1667, 1604, 1384, 1364, 1257, 1178, 850 
cm-1. 1H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H), 2.86-2.99 (m, 2H), 3.60 (m, 1H), 
3.76 (m, 1H), 3.85 (s, 3H), 4.56 (s, 2H), 4.84 (m, 1H), 5.81 (s, 1H), 6.93 (d, 2H, J = 
8.9 Hz), 7.26 (m, 3H), 7.33 (m, 2H), 7.87 (d, 2H, J = 8.9 Hz) ppm; 13C NMR (100 
MHz, CDCl3) δ 28.2, 44.2, 55.4, 57.8, 69.6, 73.1, 83.1, 106.9, 114.1, 124.2, 127.6, 
127.7, 128.4, 129.9, 137.8, 152.3, 162.7, 173.9, 175.0, 197.2 ppm; HRMS calculated 
for (C25H29NO6) requires m/z [M+Na] 462.1893, found m/z 462.1886. [α]25D = -50.8 
(c = 0.500, CHCl3). 
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(S)-6-Phenyl-2-propyl-2,3-dihydropyridin-4(1H)-one (25a): To an oven dried 10 
mL round-bottom flask charged with 20a (50.0 mg, 0.151 mmol, 1.00 equiv) in 
degassed MeOH (1 mL) was added SmI2 (4.53 mL, 0.453 mmol, 0.100 M in 
tetrahydrofuran, 3.00 equiv) under an argon atmosphere. The deep-blue solution was 
allowed to stir at room temperature until the reaction turned pale yellow (2 min) or 
deemed complete by TLC. The solvent was removed in vacuo then the residue re-
suspended in dichloromethane (20 mL). The organic layer was washed successively 
aqueous 1 M NaHSO4, H2O, brine, dried over MgSO4 and concentrated in vacuo to 
give crude compound. (33 mg, 66%). To a solution of this crude compound (33.0 mg, 
0.099 mmol) in Dichloromethane (1 mL) was added Trifluoroacetic Acid (TFA) (54 
µL). The reaction mixture was stirred until TLC showed the reaction was complete 
(~24 h). The reaction mixture was then diluted with DCM (20 mL), washed with sat. 
NaHCO3 solution and brine. The organic layer was dried (MgSO4), filtered, and 
concentrated to afford pure title compound (13.7 mg, 60%). IR (thin film) 3403, 
2900, 2858, 1617, 1531, 1384, 1325, 759, 699 cm-1. 1H NMR (400 MHz, CDCl3) δ 
1.00 (t, 3H, J = 7.3 Hz), 1.44 (m, 2H), 1.73 (m, 2H), 2.39 (m, 1H), 2.49 (m, 1H), 3.80 
(m, 1H), 4.89 (br s, 1H), 5.39 (s, 1H), 7.41-7.44 (m, 5H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 13.9, 18.8, 36.5, 41.5, 53.3, 98.2, 126.1, 129.1, 130.9, 135.9, 161.2, 193.3 
ppm; HRMS calculated for (C14H17NO) requires m/z [M+Na] 238.1208, found m/z 
 69 
238.1198. [α]25D = -61.4 (c = 0.500, CHCl3). 
 
25c
N
H
O
n-Pr
CF3
 
(S)-2-Propyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydropyridin-4(1H)-one (25c): 
To an oven dried 10 mL round-bottom flask charged with 20c (19.5 mg, 0.0488 
mmol, 1.00 equiv) in degassed MeOH (1 mL) was added SmI2 (1.47 mL, 0.147 
mmol, 0.100 M in tetrahydrofuran, 3.00 equiv) under an argon atmosphere. The deep-
blue solution was allowed to stir at room temperature until the reaction turned pale 
yellow (2 min) or deemed complete by TLC. The solvent was removed in vacuo then 
the residue re-suspended in dichloromethane (20 mL). The organic layer was washed 
successively aqueous 1 M NaHSO4, H2O, brine, dried over MgSO4 and concentrated 
in vacuo to give crude title compound. (17.8 mg, 91%). To a solution of this crude 
compound (17.8 mg, 0.0443 mmol) in Dichloromethane (1 mL) was added 
Trifluoroacetic Acid (TFA) (24.5 µL). The reaction mixture was stirred until TLC 
showed the reaction was complete (~24 h). The reaction mixture was then diluted 
with DCM (20 mL), washed with sat. NaHCO3 solution and brine. The organic layer 
was dried (MgSO4), filtered, and concentrated to afford pure title compound (9.8 mg, 
78%). IR (thin film) 3401, 2900, 1625, 1533, 1384, 1325, 827 cm-1. 1H NMR (400 
MHz, CDCl3) δ 1.00 (t, 3H, J = 7.3 Hz), 1.44 (m, 2H), 1.70 (m, 2H), 2.39 (m, 1H), 
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2.53 (m, 1H), 3.81 (m, 1H), 4.88 (br s, 1H), 5.37 (s, 1H), 7.63 (d, 2H, J = 8.2 Hz), 
7.70 (d, 2H, J = 8.2 Hz) ppm; 13C NMR (100 MHz, CDCl3) δ 13.9, 18.8, 36.5, 41.4, 
53.4, 99.7, 122.6, 126.0, 126.6, 133.0, 139.4, 159.6, 193.3 ppm; HRMS calculated for 
(C15H16F3NO) requires m/z [M+Na] 306.1082, found m/z 306.1078. [α]25D = -21.4 (c 
= 0.500, CHCl3). 
 
25d
N
H
O
n-Pr
S
 
(S)-2-Propyl-6-(thiophen-3-yl)-2,3-dihydropyridin-4(1H)-one (25d): To an oven 
dried 10 mL round-bottom flask charged with 20d (45.4 mg, 0.135 mmol, 1.00 equiv) 
in degassed MeOH (1 mL) was added SmI2 (4.04 mL, 0.404 mmol, 0.100 M in 
tetrahydrofuran, 3.00 equiv) under an argon atmosphere. The deep-blue solution was 
allowed to stir at room temperature until the reaction turned pale yellow (2 min) or 
deemed complete by TLC. The solvent was removed in vacuo then the residue re-
suspended in dichloromethane (20 mL). The organic layer was washed successively 
aqueous 1 M NaHSO4, H2O, brine, dried over MgSO4 and concentrated in vacuo to 
give crude title compound. (34 mg, 75%). To a solution of this crude compound (34 
mg, 0.10 mmol) in Dichloromethane (1 mL) was added Trifluoroacetic Acid (TFA) 
(55.3 µL). The reaction mixture was stirred until TLC showed the reaction was 
complete (~24 h). The reaction mixture was then diluted with DCM (20 mL), washed 
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with sat. NaHCO3 solution and brine. The organic layer was dried (MgSO4), filtered, 
and concentrated to afford pure title compound (19.6 mg, 88%). IR (thin film) 3271, 
2925, 1605, 1573, 1526, 1384, 1261, 787 cm-1. 1H NMR (400 MHz, CDCl3) δ 0.99 (t, 
3H, J = 7.3 Hz), 1.44 (m, 2H), 1.69 (m, 2H), 2.36 (m, 1H), 2.49 (m, 1H), 3.78 (m, 
1H), 5.03 (br s, 1H), 5.42 (s, 1H), 7.25 (m, 1H), 7.39 (m, 1H), 7.60 (m, 1H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 13.9, 18.8, 36.5, 41.6, 53.1, 98.3, 124.5, 125.4, 127.2, 
137.2, 155.7, 193.4 ppm; HRMS calculated for (C12H15NOS) requires m/z [M+Na] 
244.0772, found m/z 244.0764. [α]25D = -128.2 (c = 0.5000, CHCl3). 
 
N
H
O
Me
25e
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(S)-6-Methyl-2-propyl-2,3-dihydropyridin-4(1H)-one (25e): To an oven dried 10 
mL round-bottom flask charged with 20e (30.0 mg, 0.111 mmol, 1.00 equiv) in 
degassed MeOH (1 mL) was added SmI2 (3.34 mL, 0.334 mmol, 0.100 M in 
tetrahydrofuran, 3.00 equiv) under an argon atmosphere. The deep-blue solution was 
allowed to stir at room temperature until the reaction turned pale yellow (2 min) or 
deemed complete by TLC. The solvent was removed in vacuo then the residue re-
suspended in dichloromethane (20 mL). The organic layer was washed successively 
aqueous 1 M NaHSO4, H2O, brine, dried over MgSO4 and concentrated in vacuo to 
give crude title compound. (20.8 mg, 69%). To a solution of this crude compound 
(20.8 mg, 0.0767 mmol) in Dichloromethane (1 mL) was added Trifluoroacetic Acid 
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(TFA) (42.4 µL). The reaction mixture was stirred until TLC showed the reaction was 
complete (~24 h). The reaction mixture was then diluted with DCM (20 mL), washed 
with sat. NaHCO3 solution and brine. The organic layer was dried (MgSO4), filtered, 
and concentrated to afford pure title compound (11 mg, 100%). IR (thin film) 3271, 
2967, 2926, 1617, 1592, 1533, 1384 cm-1. 1H NMR (400 MHz, CDCl3) δ 0.96 (t, 3H, 
J = 7.3 Hz), 1.37-1.43 (m, 2H), 1.57-1.65 (m, 2H), 1.96 (s, 3H), 2.21-2.29 (m, 1H), 
2.36-2.41 (m, 1H), 3.62 (m, 1H), 4.56 (br s, 1H), 4.95 (s, 1H) ppm; 13C NMR (100 
MHz, CDCl3) δ 13.9, 18.6, 21.3, 36.6, 41.2, 53.2, 99.5, 161.3, 192.8 ppm; HRMS 
calculated for (C9H15NO) requires m/z [M+Na] 176.1051, found m/z 176.1045. [α]25D 
= -15.8 (c = 0.500, CHCl3). 
 
N
H
O
25f
n-Pr
 
(S)-6-tert-Butyl-2-propyl-2,3-dihydropyridin-4(1H)-one (25f): To an oven dried 10 
mL round-bottom flask charged with 20f (52.4 mg, 0.168 mmol, 1.00 equiv) in 
degassed MeOH (1 mL) was added SmI2 (5.05 mL, 0.505 mmol, 0.100 M in 
tetrahydrofuran, 3.00 equiv) under an argon atmosphere. The deep-blue solution was 
allowed to stir at room temperature until the reaction turned pale yellow (2 min) or 
deemed complete by TLC. The solvent was removed in vacuo then the residue re-
suspended in dichloromethane (20 mL). The organic layer was washed successively 
aqueous 1 M NaHSO4, H2O, brine, dried over MgSO4 and concentrated in vacuo to 
 73 
give crude title compound. (52.1 mg, 99%). To a solution of this crude compound 
(52.0 mg, 0.166 mmol) in Dichloromethane (1 mL) was added Trifluoroacetic Acid 
(TFA) (91.7 µL). The reaction mixture was stirred until TLC showed the reaction was 
complete (~24 h). The reaction mixture was then diluted with DCM (20 mL), washed 
with sat. NaHCO3 solution and brine. The organic layer was dried (MgSO4), filtered, 
and concentrated to afford pure title compound (32.4 mg, 100%). IR (thin film) 3301, 
2959, 2925, 1605, 1513, 1465, 1384, 1364, cm-1. 1H NMR (400 MHz, CDCl3) δ 0.97 
(t, 3H, J = 7.3 Hz), 1.18 (s, 9H), 1.43 (m, 2H), 1.63 (m, 2H), 2.23 (dd, 1H, J1 = 12.6 
and J2 = 16.1 Hz), 2.40 (dd, 1H, J1 = 4.9 and J2 = 16.1 Hz), 3.59 (m, 1H), 4.76 (br s, 
1H), 5.12 (s, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 13.9, 18.7, 28.6, 35.3, 36.3, 
41.1, 53.1, 96.0, 172.6, 193.4 ppm; HRMS calculated for (C12H21NO) requires m/z 
[M+Na] 218.1521, found m/z 218.1518. [α]25D = -73.4 (c = 0.500, CHCl3). 
 
25i
N
H
O
OMe
BnO
 
(R)-2-(Benzyloxymethyl)-6-(4-methoxyphenyl)-2,3-dihydropyridin-4(1H)-one 
(25i): To an oven dried 10 mL round-bottom flask charged with 20i (40.0 mg, 0.0910 
mmol, 1.00 equiv) in degassed MeOH (1 mL) was added SmI2 (2.73 mL, 0.273 
mmol, 0.100 M in tetrahydrofuran, 3.00 equiv) under an argon atmosphere. The deep-
blue solution was allowed to stir at room temperature until the reaction turned pale 
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yellow (2 min) or deemed complete by TLC. The solvent was removed in vacuo then 
the residue re-suspended in dichloromethane (20 mL). The organic layer was washed 
successively aqueous 1 M NaHSO4, H2O, brine, dried over MgSO4 and concentrated 
in vacuo to give crude compound. (30 mg, 75%). To a solution of this crude 
compound (30.0 mg, 0.0686 mmol) in Dichloromethane (1 mL) was added 
Trifluoroacetic Acid (TFA) (53.3 µL). The reaction mixture was stirred until TLC 
showed the reaction was complete (~24 h). The reaction mixture was then diluted 
with DCM (20 mL), washed with sat. NaHCO3 solution and brine. The organic layer 
was dried (MgSO4), filtered, and concentrated to afford pure title compound (16.4 
mg, 75%). IR (thin film) 3401, 2918, 1604, 1508, 1384, 1258, 833 cm-1. 1H NMR 
(400 MHz, CDCl3) δ 2.36 (m, 2H), 3.63 (m, 2H), 3.85 (s, 3H), 3.99-4.07 (m, 1H), 
4.59 (s, 2H), 5.37 (s, 1H), 5.47 (br s, 1H), 6.94 (d, 2H, J = 8.8Hz), 7.32-7.37 (m, 5H), 
7.45 (d, 2H, J = 8.8 Hz) ppm; 13C NMR (100 MHz, CDCl3) δ 37.7, 52.7, 55.5, 71.6, 
73.4, 97.9, 114.4, 127.5 127.9, 128.1, 128.6, 137.4, 160.9, 161.8, 191.8 ppm; HRMS 
calculated for (C20H21NO3) requires m/z [M+Na] 346.1419, found m/z 346.1418. 
[α]25D = -86.4 (c = 0.500, CHCl3). 
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